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3ABSTRACT
The t(12;21)(p13;q22) translocation is present in up to 25% of children
with pre-B cell Acute Lymphoblastic Leukaemia (ALL). This translocation
involves two transcription factors, TEL (ETV6) and AML (RUNX1), both of
which have crucial roles in regulating haematopoiesis. Clinically, TEL-AML1
positive patients have good prognoses. However, late relapses, additional
genetic lesions affecting prognosis, and long-term side-effects of chemotherapy
remain a cause for concern. In light of recent studies showing genetic and
functional heterogeneities in cells responsible for cancer clone maintenance
and propagation, targeting common deregulated pathways may be critical for
the success of novel therapies.
Using Affymetrix GeneChip global gene expression analysis our
laboratory previously identified three genes: Tbx2, E2f5 and Lif-R, specifically
expressed in TEL-AML1 transduced mouse foetal liver haematopoietic
progenitor cells (HPC) cells compared with control cells. Over-expression of
these genes was confirmed by real-time qPCR and the specificity of target
gene expression was evaluated in human TEL-AML1 positive and negative
leukaemia cells. Pathway analysis of TEL-AML1 transcriptional target genes
also demonstrated deregulated expression of genes associated with STAT3
signalling, known to be one of the most important pathways required for
proliferation and maintenance of multipotency in cancer stem cells.
4In this study we demonstrate the importance of STAT3 activity in a
mouse model of TEL-AML1 overexpression, in human TEL-AML1 positive
leukaemia cells and primary human leukaemic samples. Our data indicate a
central role for TEL-AML1 in maintaining activated STAT3. This is mediated by
transcriptional induction of the Guanine nucleotide exchange factor, ARHGEF4,
leading to RAC1 activation and consequent stimulation of STAT3. The latter is
necessary for survival, proliferation and self-renewal of TEL-AML1 positive
leukaemia through transcriptional induction of MYC expression. In conclusion,
we show a novel signalling pathway important for maintenance of t(12;21)
leukaemia that constitutes a promising novel therapeutic target for the
treatment of this disease.
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CHAPTER I
1.1 Haematopoiesis
Haematopoiesis is the name given to the process of blood cell
production. Millions of blood cells are replaced by new ones every second
during our life, making blood the most regenerative and plastic tissue present in
the human body (Rieger and Schroeder, 2012). This characteristic is effective
during emergency situations, such us infection or during bleeding, where blood
cell counts have to rapidly increase. All the different blood cell types arise from
a small population of cells called haematopoietic stem cells (HSCs) that during
adult life reside mainly in the bone marrow (BM), the major site of adult
haematopoiesis (Rieger and Schroeder, 2012).
Most of the studies to understand haematopoiesis have been done in
mice and currently this is the best understood of all species. The use of
genetically modified mice for the gain- or loss- of function of specific genes
controlling haematopoiesis has facilitated experimental analysis of
haematopoiesis in vivo. Moreover, the use of conditional mutants, that confer
specific expression of particular genes only in haematopoietic cells, has further
permitted the study of the function of many genes in different cell lineages (de
Boer et al., 2003; Kuhn et al., 1995). However, haematopoiesis has also been
studied in other experimental organisms. The use of animal models such as the
Zebrafish and Drosophila melanogaster is revealing many important insights,
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mainly due to the faster and cheaper genetic manipulation of these organisms
(Crozatier and Vincent, 2011; Jing and Zon, 2011).
In human, as in mice, the generation of the first cells with the functional
property to regenerate the haematopoietic system upon transplantation into
recipient mice, that is the principal characteristic of HSCs, occurs in the
intraembryonic aorta-gonad-mesonephros (AGM) region and the placenta
(Gekas et al., 2005; Ivanovs et al., 2011). Before this, haematopoietic cells are
generated firstly in the extraembryonic yolk sac then in the allantois and
placenta. In addition, there is also evidence for production of transient
populations of blood cells in the early stages of the embryo. Thus, primitive
erythrocytes, that still have the nucleus, primitive macrophages and
megakaryocytes are present in the extraembryonic yolk salk before HSCs and
then disappear as the embryo develops further (Chen et al., 2011). After being
generated in the AGM, HSCs migrate to the foetal liver, the major site for their
expansion. Shortly thereafter they migrate to the spleen and around birth to the
bone marrow, which becomes the main site of HSC-derived haematopoiesis
after birth (Figure 1-1). The tissue origin of these HSCs has only recently been
solved in mice. Thanks to time-lapse microscopy, Eilken and colleagues were
able to detect a continuous endothelial to haematopoietic transition in mice,
subsequently confirmed by another two studies in Zebrafish embryos (Bertrand
et al., 2010; Eilken et al., 2009; Kissa and Herbomel, 2010). The spatial and
temporal similarities that exist between mouse and human haematopoiesis
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suggest that the same mechanisms may also be involved in human embryonic
haematopoiesis.
During adult haematopoiesis, all blood lineages derive from a small
number of HSCs mainly located in the bone marrow. These cells have two
different capacities, they have the potential to self-renew and they can
differentiate into various haematopoietic progenitor cells (HPCs), which in turn
are further able to differentiate in all the blood lineages (Till and McCulloch,
1980). The generation of new cells occurs in a hierarchical manner, HSCs
being located at the apex and cells lower down in the hierarchy having an
increasingly restricted lineage potential. The different populations of cells are
mainly identified by multiple surface markers (lineage markers). Although there
are many similarities between human and mouse haematopoiesis, HSCs from
the two species express different markers. Human HSCs, in contrast to mouse
HSCs, in fact do not express the markers Sca1 and the signalling lymphocyte
activation molecule family member 1 (SLAM1/CD150) (Larochelle et al., 2011).
Additionally, while the CD34+/CD38- phenotype was regarded as the canonical
marker set for human HSCs, mouse HSCs are mainly located within the CD34-
/CD38+ population (Matsuoka et al., 2001; Tajima et al., 2001). The highest
purity of human HSCs can be found within the Lin-/CD34+/CD34RA-
/CD90+/Rhodamine123low/CD49f+ population (Notta et al., 2011). However, a
very recent paper has challenged this distinction, showing not only that a
population of CD34- cells with HSC features is present in human bone marrow,
but that it can also be placed above the CD34+ population in the
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haematopoietic hierarchy suggesting more similarity between mouse and
human haematopoiesis than previously appreciated (Anjos-Afonso et al.,
2013).
From this small population, cells differentiate into a cascade of
progenitors with diminishing multilineage potential, before unilineage
commitment occurs. The first population that arises from HSCs is the
multipotent progenitor (MPP) subset that retains multi-lineage differentiation
potential but differs from the original population in lacking self-renewal ability
(Reya, 2003). The existence of this population has been discovered both in
human and mouse. From these cells arise two different populations of
progenitors. The first one, that loses the ability to give rise to erythroid and
megakaryocytic lineages, is the early lymphoid progenitor cell population
[MLPs in human and lymphoid-primed multipotent progenitor (LMPPs) in
mouse] that is largely lymphoid restricted but possesses also myeloid, but not
erythroid and megakaryocytic, potential. MLPs/LMPPs generate B and T
lymphocytes and natural killer (NK) cells, but they can also differentiate into
granulocyte/monocyte progenitors (GMPs) or completely differentiated myeloid
cells (Adolfsson et al., 2005). The second population is the common myeloid
progenitor population (CMP), that produces GMPs and
megakaryocyte/erythroid progenitors (MEPs) which differentiate into
monocytes and granulocytes, and erythrocyte and megakaryocytes,
respectively (Doulatov et al., 2012) (Figure 1-2).
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1.1.1 Molecular control of haematopoiesis
Transcription factors play fundamental roles during haematopoiesis,
controlling stem cell maintenance, lineage commitment and differentiation. In
HSCs, transcriptional regulation is focused on maintaining the capacity for self-
renewal and promotion of cell survival. There are many factors involved in the
control of self-renewal. One of the most important genes able to maintain self-
renewal is Homeobox A9 (Hoxa-9). This gene is the highest expressed of the
Hox family in HSC and knock-out studies demonstrated that HSC derived from
Hoxa-9-/- mice were unable to reconstitute the haematopoietic system of
transplanted recipient mice (Lawrence et al., 2005). The same result is also
found following ablation of the growth factor independence 1 (Gli1) gene,
presumably due to the fact that the encoded factor is a repressor of p53
activity, a factor essential for the quiescent status of HSCs (Liu et al., 2009;
Zeng et al., 2004). Another group of genes important for HSC self-renewal
encode the polycomb group proteins (PcGs). In particular, animals deficient for
the polycomb ring finger oncogene (Bmi1), a member of this family, showed
reduced levels of HSC self-renewal activity and an increased rate of
differentiation (Iwama et al., 2004). The balance between stem cell self-renewal
and differentiation has been shown also to be controlled by the v-myc avian
myelocytomatosis viral oncogene homolog (c-MYC) presumably by controlling
the interactions between HSCs and their niche by regulating the expression of
N-cadherin and integrins (Wilson et al., 2004). The main factors responsible for
HSC survival are the proteins belonging to the B-cell lymphoma 2 (BCL-2)
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family, such as the myeloid cell leukaemia sequence 1 (MCL1) factor
(Opferman et al., 2005; Orelio and Dzierzak, 2007). All these functions are
regulated by extracellular stimuli that control pathways regulating networks of
transcription factors. The main pathways responsible for the regulation of self-
renewal in HSCs are the wingless-type MMTV integration site family (WNT)
and the Janus kinase (JAK)- signal transducer and activator of transcription
(STAT) pathways. The WNT ligands bind to a receptor complex consisting of a
member of the Frizzled family and the low density lipoprotein (LDL) receptor-
related proteins LRP5 or LRP6. In the canonical WNT pathway, receptor
activation leads to stabilization of β-catenin, which accumulates and 
translocates to the nucleus where it activates target gene expression (Clevers,
2006). Addition of WNT proteins or over-expression of the constitutive active
form of β-catenin leads to increased self-renewal activity in vitro and
haematopoietic reconstitution ability in vivo (Reya and Clevers, 2005). Many
cytokine receptors that lack catalytic activity can transduce signals into the cell
through the JAK-STAT pathway (see section 5.1). Due to the wide variety of
stimuli that can activate this signalling pathway it can profoundly influence
HSCs self-renewal. For example, activation of STAT5, one of the main
mediators of the pathway, was shown to induce long-term self-renewal in
human HSCs (Fatrai et al., 2011; Schuringa et al., 2004).
Extracellular stimuli are also capable of influencing haematopoietic
lineage choice. Cytokines, extracellular matrix and membrane-bound signalling
molecules can influence and regulate lineage commitment. These stimuli are
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converted inside the cells into gene expression changes by networks of
transcription factors that regulate the cell fate choice. Cytokines, can be lineage
speciﬁc or can regulate cells in multiple lineages, and, for some cell types, the 
concurrent action of different cytokines is required for the final outcome. The
main group of cytokines responsible mainly for myeloid lineage commitment is
the colony stimulating factor (CSF) family. There are four different CSFs, each
with differing colony-stimulating activity. The given working names indicate the
most numerous type of colony stimulated in colony forming assays: GM-CSF
(CSF2) stimulates granulocyte and macrophage colony formation; M-CSF
(CSF1) stimulates macrophage colony formation; G-CSF (CSF3) stimulates
granulocyte colony formation; and multi-CSF (IL-3) stimulates a broad range of
haematopoietic cell colony types (Metcalf, 2010). One of the main cytokines
responsible for lymphoid commitment is IL-7. Mice deﬁcient for IL-7 or any 
component of its receptor exhibit severely impaired B and T lymphopoiesis
since the common lymphoid progenitor (CLP) compartment is dramatically
reduced in these mutant mice (Peschon et al., 1994; Puel et al., 1998;
Tsapogas et al., 2011; von Freeden-Jeffry et al., 1995). Evidence that
cytokines can direct the lineage commitment comes also from experiments
demonstrating the ability of cytokines to redirect specification in cells already
committed to a particular lineage. Ectopic expression of the IL-2 receptor in
CLPs, for instance, can convert their cell fate from lymphoid to myeloid (Kondo
et al., 2000). Similarly, GM-CSF receptor signalling can redirect IL-7 receptor-
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deﬁcient lymphoid progenitors to the myeloid cell lineage (Iwasaki-Arai et al., 
2003)
These experiments support an inductive model for haematopoietic
differentiation (Metcalf, 1991). In contrast to this model, an alternative
hypothesis has been proposed stating that intrinsic molecular events within
cells determine their lineage commitment, known as stochastic haematopoietic
development (Ogawa, 1994). Supporting the latter model, different lineage-
specific transcription factors have been shown to be co-expressed in
multipotent cells before lineage commitment and these proteins often inhibit
each other transcriptionally or form multiprotein complexes that are not able to
function normally (Palani and Sarkar, 2009). For this reason, random
fluctuations of transcription factor expression could lead to a particular one
gaining dominance and thereby regulating the differentiation process. In the
stochastic model, moreover, cytokine signalling has been seen as a secondary
event to transcription factor lineage specification, in the sense that transcription
factor activated cytokine receptor expression permits the survival and
amplification of the stochastically committed cells (Cross et al., 1997) (Figure 1-
3).
1.1.2 B-cell biology and development
B-lymphocyte cells develop in the bone marrow from HSCs. The B-cell
specification process is best understood in the mouse where lymphoid
31
commitment starts at the lymphoid-primed multipotent progenitor (LMPPs)
stage and continues in common lymphoid progenitors in order to initiate B cell
specification through the pre-pro B stage and the pro-B stages where the
rearrangement of the immunoglobulin heavy chain (IgH) locus is initiated.
Successful IgH gene rearrangement generates pre-B cells that express the
pre-B-cell receptor (pre-BCR) and these then undergo rearrangement of the Ig
light chain loci to further differentiate into immature B cells. This commitment
requires a hierarchical regulation of many transcription factors that has been
mostly elucidated. Generally, during these transitions, gene expression
associated with multipotency and stemness gives way to expression of genes
associated with the B cell fate (Figure 1-4).
One of the first key regulators is IKAROS (IKZF1), a transcription factor
with an N-terminal conserved zinc-finger domain that mediates DNA binding
and a C-terminal zinc-finger domain required for homo- and heterodimerization.
IKZF1 can function either as a transcriptional activator or repressor, recruiting
various different chromatin remodelling complexes (Kim et al., 1999). It plays a
fundamental role in lymphoid commitment and specification since Ikzf1-/- mice
are completely deficient in NK cells, B and T cells and, specifically, in B cell
development they lack the pre-pro-B cell transitional population (Georgopoulos
et al., 1994; Wang et al., 1996). This data was further confirmed with
homozygous mice bearing a hypomorphic Ikzf1 allele (Kirstetter et al., 2002).
The main function of this transcription factor in lymphoid development is to
suppress the expression of genes associated with stemness and myeloid
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associated genes and to induce expression of lymphoid specific genes (Ng et
al., 2009). Another essential regulator at the LMPP stage of lymphoid
specification and restriction of myeloid potential is E2A, a protein belonging to
the E protein (class I) family of helix-loop-helix transcription factors (Dias et al.,
2008). Progenitor cells lacking of this factor fail to generate pro-B cells (Zhuang
et al., 1994). Moreover, similar to IKZF1, E2A is able to regulate the expression
of important factors required for B-cell commitment. These two transcription
factors cooperate to induce B cell lineage specific genes, including two of the
main genes necessary for B cell commitment. Thus, they are both able to
regulate the expression of the gene encoding for the IL-7 receptor (IL-7R) (Dias
et al., 2008; Yoshida et al., 2006). This expression is necessary for complete B
specification since deficiency in the IL-7R, or IL-7 itself, leads to an early block
in B cell development, specifically at the pro-B stage (Peschon et al., 1994; von
Freeden-Jeffry et al., 1995). This block is mainly due to impaired recombination
of the VH gene segment that is regulated mainly by the STAT proteins
(Corcoran et al., 1998; Goetz et al., 2004). Furthermore, they also regulate the
expression of the early B-cell factor 1 (EBF1) gene. Interestingly, the factor
encoded by this gene is able to rescue the aberrant B lymphoid phenotype in
Ikz1-/- mice and E2a deficient cells (Reynaud et al., 2008; Seet et al., 2004;
Smith et al., 2002). The importance of this gene has been also shown in Ebf1-/-
mice, where its absence results in an absolute block in differentiation at the
pre-pro-B stage (Lin and Grosschedl, 1995). The key function of EBF1 is to
induce the expression of the guardian and main regulator of B-cell identity,
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Paired box 5 (PAX5). Pax5 gene expression is initiated at the pro-B cell stage
(Fuxa and Busslinger, 2007) and during early stages of commitment is subject
to allele-specific regulation with only one allele being transcribed in any given
cell. This switches to bi-allelic expression only at later stages of B cell
commitment (Nutt et al., 1999b). Similar to the other B cell specific transcription
factors, PAX5 is known to maintain B cell identity through the transcriptional
activation of B cell specific genes and repression of genes associated with
other lineages. Interestingly, the set of target genes regulated by PAX5 is
different in early and late B lymphopoiesis, suggesting an essential role for this
factor for the final commitment (Revilla et al., 2012). Experiments with Pax5
deficient embryos showed, moreover, a lack of B lymphopoiesis in the foetal
liver whereas B cell development proceeded to a progenitor-cell stage in the
bone marrow suggesting a differential requirement for Pax5 in foetal and adult
B lymphopoieisis (Nutt et al., 1997; Urbanek et al., 1994). However, the bone
marrow progenitor cells were not committed to the B lineage, as in vitro culture
of these cells in presence of specific lineage cytokines allowed them to
differentiate into functional macrophages, granulocytes, dendritic cells,
osteoclasts and NK cells (Nutt et al., 1999a). Additionally, conditional
inactivation of Pax5 in mature peripheral B cells resulted in de-differentiation to
lymphoid progenitors which could give rise to functional T cells in vivo
(Cobaleda et al., 2007a).
As already mentioned activation of B cell-specific genes and
simultaneously shutting down the expression of B cell inappropriate genes is
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the fundamental function of PAX5 during B cell lineage commitment.
Regulation of the expression of genes involved in the signal transduction of the
pre-BCR and, subsequently of the BCR, such as CD19 and CD21 indicates
that PAX5 plays a fundamental role for the pre-B to differentiate into a
population of cells, named immature B cells, ready to leave the bone marrow to
further differentiate in the peripheral lymphoid organs (Cobaleda et al., 2007b).
Thus, during this stage the cells are subjected to negative and positive
selection in order to select for B cells with functional surface expression of BCR
and eliminate B cells with overt reactivity to self-antigen, ensuring maintenance
of immunological self-tolerance (Sandel and Monroe, 1999). After this
selection, cells migrate into peripheral tissues and remain inactive until they
encounter pathogen. Depending of the antigen source, full stimulation of B cells
can be (thymus-dependent activation) or not (thymus-independent activation)
mediated by T cells. The more common activation is given by activated
antigen-specific helper T cells, which stimulate B cells to proliferate and form
germinal centres where they differentiate into memory B cells or plasma cells
responsible of antibody secretion.
1.1.3 Alterations in haematopoietic transcription factor genes
Genetic alterations, such as mutations, deletions or translocation, of
many of the genes encoding transcription factors essential for foetal
haematopoiesis and lineage commitment, in most cases cause severe
haematopoietic problems or even embryonic death. Appropriate expression of
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genes during haematopoietic development and differentiation is extremely
important and the failure of these mechanisms may lead to arrested
differentiation and cellular transformation, ultimately causing the disease known
as leukaemia.
1.2 Acute lymphoblastic leukaemia
The haematopoietic progenitor cells of each committed lineage are also
called blasts, for example lymphoblasts or myeloblasts, and in normal
conditions they represent less than 5% of the cells made in the bone marrow.
When the blasts of one lineage represent more than 20% of the total amount of
cells and, in some cases, are found in the peripheral blood, this is considered a
pathological status known as leukaemia (Harris et al., 1999). Leukaemia is
clinically and pathologically subdivided into a variety of large groups. The first
division is between its acute and chronic forms. Subsequently, it is subdivided
according to which kind of blood progenitor cell is affected. This split divides
leukaemia into lymphoblastic and myeloid leukaemia (Harris et al., 1999).
Acute Lymphoblastic Leukaemia (ALL) is a malignant disorder of
lymphoid progenitor cells. It affects both children and adults, but the peak
prevalence is between the ages of 2 and 5 years, and it is the most commonly
occurring cancer in children, representing 30% of all paediatric tumours.
Although the overall survival rate is currently almost 90%, it remains one of the
main causes of cancer deaths in children (Pui et al., 2011). Moreover, in
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developed countries the incidence of this disease has increased by
approximately 1% per year over the past two decades (Linabery and Ross,
2008).
The general mechanisms underlying the induction of ALL include the
aberrant expression of proto-oncogenes, chromosomal translocations that
create fusion genes encoding active kinases or altered transcription factors,
and hyperdiploidy (Chen et al., 2010). These genetic alterations contribute to
the leukaemic transformation of hematopoietic stem cells or their committed
progenitors by changing cellular functions. In fact, they can alter key regulatory
processes by maintaining or enhancing an unlimited capacity for self-renewal,
subverting the controls of normal proliferation, blocking differentiation, and
promoting resistance to death signals (apoptosis) (Pui et al., 2004). The
majority of ALLs are represented by a pre-B-cell phenotype, displaying cell
surface marker expression associated with normal pre-B cells, although
approximately 20% also exhibit aberrant myeloid lineage specific cell surface
antigen expression (Firat et al., 2001). However, the leukaemic cells are
blocked at this particular stage of the differentiation process and accumulate in
the body (Inaba et al., 2013).
1.2.1 t(12;21) Acute Lymphoblastic Leukaemia
One of the main alterations associated with ALL is the balanced
chromosomal translocation that often involves the in-frame fusion of genes
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encoding transcription factors which play critical roles in normal
haematopoiesis. The most frequent single gene recombination in paediatric
cancer is the t(12;21)(p13;q22) rearrangement, representing more than the
20% of all paediatric acute lymphoblastic leukaemia cases (Mullighan, 2012)
(Figure 1-5). This translocation involves two genes encoding transcription
factors: ETS translocation variant 6 (ETV6) also known as translocation–Ets-
leukemia (TEL) that maps on chromosome 12 and Runt-related transcription
factor 1 (RUNX1) also known as Acute myeloid leukemia 1 protein (AML1) that
maps on chromosome 21 (Romana et al., 1994).
Both TEL (ETV6) and AML1 (RUNX1) are transcription factors involved
in normal haematopoiesis. They have been shown to be essential for the
establishment of haematopoiesis of all lineages in the bone marrow and
constitutive loss of either one of the genes encoding them is embryonic lethal
(Wang et al., 1998). AML1 belongs to the Runt-related transcription factor
(RUNX) family of genes, also called core binding factor (CBF) genes, and its
expression is primarily restricted to cells of the haematopoietic lineage (Corsetti
and Calabi, 1997). It is required for hematopoiesis in the embryonic stage but,
in contrast, loss of AML1 in the adult does not cause complete loss of
hematopoiesis. Specifically, it has been shown, using conditional knockout
mice, that Aml-1 is required for maturation of megakaryocytes and
differentiation of T and B cells, but not for maintenance of HSC during adult
haematopoiesis (Ichikawa et al., 2004). Moreover, a recent paper showed that
it is necessary for survival and development of B-cell-specified progenitors
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showing, in addition, the occupancy of enhancer regions of genes critical for
pre-B-cell transition (Niebuhr et al., 2013). The highly evolutionarily conserved
Runt domain is responsible for both DNA binding and heterodimerization with
the partner protein, core-binding factor β (CBFβ) (Figure 1-6A). Although the 
protein alone is able to regulate the expression of many genes, binding to the
CBFβ subunit  increases DNA binding affinity and protects RUNX1 from 
ubiquitin-proteosome-mediated degradation (Huang et al., 2001). The TEL
gene encodes the E-twenty six (ETS) family transcription factor ETV6, which is
an essential regulator of post-natal HSCs. It is required for the establishment of
hematopoiesis of all lineages in the bone marrow. Hematopoietic stem cells or
progenitors need this factor in order to migrate or home to the bone marrow
from the foetal liver, or to respond appropriately to the signal from the bone
marrow niche and survive within the bone marrow microenvironment (Hock et
al., 2004; Wang et al., 1997; Wang et al., 1998). The protein has three main
domains: the N-terminal pointed domain (PD) which mediates protein-protein
interactions, including ETV6 oligomerisation, a C-terminal DNA-binding domain
and a central domain that is mainly involved in the recruitment of repression
complexes (Poirel et al., 1997) (Figure 1-6B).
The translocation between these two genes creates a fusion transcript
that includes sequences encoding the PD domain of TEL, but not its DNA-
binding domain, and almost the entire coding region of AML1 (Figure 1-6C).
Although the presence of the t(12;21) translocation is detectable years before
the clinical onset of disease, and occurs most likely in utero, on its own it is not
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sufficient to induce frank leukaemia (Zelent et al., 2004) (Figure 1-7). Indeed it
generates a pre-leukaemic clone that requires secondary mutations in order to
induce leukaemic transformation. One of the more recent hypotheses suggests
that acute lymphoblastic leukaemia could be a result of an abnormal response
to a common infection. Based on this idea, two different possible mechanisms
have been suggested. According to Kinlen’s “population mixing” theory, ALL
could arise as a consequence of non-immune children exposed to some
unknown infection(s), through population movement and mixing (Kinlen, 1995).
In contrast, a distinct hypothesis, known as “delayed infection theory”, states
that ALL may arise from a lack of exposure to infectious agents at a younger
age. Later, this deficiency may result in an abnormal immune response to
otherwise common infections, which would create a favorable environment to
promote leukemic transformation (Greaves, 2006).
There is a large discrepancy between the frequency of normal cord
blood samples positive for the presence of the translocation and the incidence
of ALL. Some studies suggest that only 1 of 100 newborns with detectable
TEL-AML1 transcripts are destined to develop ALL (Mori et al., 2002). In
contrast, others propose a model in which the initiating event is as rare as the
disease itself, implying that a high proportion (perhaps 100%) of babies born
with the TEL-AML1 fusion are destined to develop leukaemia (Lausten-
Thomsen et al., 2011). This difference in frequency is still a matter for debate
but the “two hit” model best explains the biology of the disease, suggesting that
the secondary genetic alteration is necessary and may represent the limiting
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factor for the development of the disease (Mori et al., 2002) (Figure 1-8). This
is also suggested by analysis of blood from healthy adults that also
demonstrated the presence of the fusion gene (Olsen et al., 2006).
In patients, this translocation is detected in leukaemic blasts that appear
to be blocked at an early stage of B-lymphoid lineage differentiation, when they
initiate but fail to complete immunoglobulin gene rearrangement (Panzer-
Grumayer et al., 2005; Pui et al., 2004; Sloma and Eaves, 2009). The most
immature TEL-AML1+ population is in fact identified by the aberrant
CD34+CD38–CD19+ phenotype, that has been associated with a very early
stage of lineage commitment (Hong et al., 2008). Thus far, no experimental
models of t(12;21) leukaemia in mice have been able to recapitulate a definite
B-ALL phenotype, regardless of the timing and mode of TEL-AML1 expression.
The first generation of TEL-AML1 transgenic mice was performed using the
immunoglobulin heavy chain enhancer/promoter to drive the expression of the
human fusion gene in lymphoid cells. But although expression was confirmed,
the mice did not develop a malignant haematological disorder or any signs of
alteration in the haematopoiesis (Andreasson et al., 2001). In addition, a
different approach was used by several groups, transplanting into irradiated
mice bone marrow cells transduced with a retrovirus expressing the fusion
gene. In one of the studies, over-expression of the fusion caused leukaemia in
two of the nine transplanted mice (one T-lineage ALL and one B-precursor
ALL) whereas in the other two only accumulation of both multipotent and B-cell
progenitors was shown (Bernardin et al., 2002; Fischer et al., 2005; Tsuzuki et
41
al., 2004). A similar study, but using foetal haematopoietic cells, exhibited,
instead, an increase in repopulation of myeloid cells and B cells, although the
differentiation of TEL-AML1+ cells remained unperturbed (Morrow et al., 2004).
Two more recent studies created knock-in mouse models where TEL-AML1
expression was driven from the endogenous Tel promoter (Schindler et al.,
2009; van der Weyden et al., 2011). Expression of the fusion gene alone did
not cause disease in either study, but increased numbers of HSC and a
transient increase in foetal B progenitor self-renewal was observed in one of
the models (Schindler et al., 2009). However, both mouse models exhibited
predisposition to development of leukaemia following mutagenesis. In
particular, Schindler and colleagues showed that induction of T-cell leukaemia
following treatment with the N-ethyl-N-nitrosourea (ENU) mutagen was faster
and more penetrant in knock-in mice compared to controls. More interestingly,
van der Weyden and colleagues, using the Sleeping Beauty (SB) transposase,
were able to obtain B-ALL in almost 20% of the mice (Schindler et al., 2009;
van der Weyden et al., 2011).
The difficulty in accurately modelling TEL-AML1+ ALL may be due to
weak oncogenic activity of this fusion, which may require secondary genetic
changes to complete the transformation from the pre-leukaemic to the
leukaemic clone. This possibility is supported by studies on ALL in identical
twins. Although both twins frequently contain cells with the identical TEL-AML1
fusion, the latency of ALL is often markedly different in each affected individual,
with one of the twins in some cases failing to develop the disease at all (Ford et
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al., 1998; Hong et al., 2008). The knock-in mouse model generated by
Schindler et al demonstrated that TEL-AML1 expression in HSC results in a
persistent pre-malignant population susceptible to the accumulation of further
genetic hits for the progression to malignancy (Schindler et al., 2009). The
most frequent secondary genetic abnormalities include the loss of the DNA
region encompassing the second allele of TEL and deletion of part of
chromosome 9, including the PAX5 and CDKN2A loci (Mullighan et al., 2007).
However, the multistep process that ultimately results in overt leukaemia
remains poorly understood.
The biology of pre-leukaemic TEL-AML1+ cells is not well understood
either. Some evidence suggests that pre-leukemic clones can be propagated
after B-lineage commitment. In fact, analysis of immunoglobulin receptor
rearrangements and retroviral transduction of TEL-AML1 in human and mouse
models suggested that the fusion may promote self-renewal of early B cells
(Ford et al., 1998; Hong et al., 2008; Morrow et al., 2004). Recent findings,
moreover, demonstrate that TEL-AML1 may play a role in down-regulating the
expression of genes encoding the Spi-B transcription factor (SPIB) and IKZF3,
two regulators of the pre-B transition, suggesting a function of the fusion in
blocking the B cell specification process (Niebuhr et al., 2013). Taken together,
these findings could explain the block in B cell differentiation and the
accumulation in the blood of pre-leukemic clones (Niebuhr et al., 2013).
The most common hypothesis for how TEL-AML1 functions is that it acts
as an antagonist of endogenous RUNX1 transcriptional activity. Transient over-
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expression of the fusion protein is able to repress the activity of reporter
constructs of haematopoietic-specific genes and/or antagonize RUNX1
dependent transcriptional activity (Fears et al., 1997; Hiebert et al., 1996;
Uchida et al., 1999). This repression may be due to the ability of ETV6 to
recruit nuclear receptor/histone deacetylase (HDACs) complexes, mainly
through the PD, such as mSin3A, n-CoR and HDACs, forming stable repressor
complexes (Petrie et al., 2003; Wang and Hiebert, 2001) (Figure 1-9).
However, recent evidence from Panzer-Grümayer’s group also suggests that
TEL-AML1 may play a role in promoting the expression of particular
downstream target genes. Although the conclusion of this work was in
agreement with the hypothesis that TEL-AML1 represses RUNX1 target genes,
the macro-array analysis, following shRNA-mediated knock-down of the fusion
gene in human leukaemic cell lines, revealed that PI3K/AKT/mTOR signalling
and the HSC gene expression signatures were highly enriched in the list of
down-regulated genes (Fuka et al., 2011). In particular the PI3K/AKT/mTOR
signature appeared to be necessary for the survival of TEL-AML1 leukaemia
(Fuka et al., 2012). These findings suggest that the fusion gene may also have
an active role in upregulating the expression of genes fundamental to the
activity of oncogenic pathways and not only function as an antagonist of wild-
type RUNX1. Identifying and characterising the transcriptional cascades and
signalling pathways deregulated by TEL-AML1 is therefore essential to
understanding how this fusion protein promotes leukaemia in children.
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1.3 Aim of the study: Cancer signalling and targeted
therapy
Most cancers are multistep processes of malignant transformation that
require activation or down-regulation of several cellular processes. A defect in
every process is often associated with alteration of a particular transcription or
signalling pathway in the cell that can alter normal programs of proliferation,
transcription, growth, migration, differentiation and death. In the last 10 years
the identification of these pathways has allowed the discovery of new drug
targets for cancer treatment, specific for many different tumours subtypes.
Moreover, considerable attention has been directed towards the identification
of the oncoproteins necessary for particular cancers, in order to target the
specific factor or pathways affected with a selected drug (oncogene addiction)
(Weinstein, 2002). For example, impressive results have been obtained in
treatment of selected cohorts of patients harbouring oncogene-addicted
tumours. The drug Imatinib (Gleevec), an inhibitor of the tyrosine kinase
activity of the BCR-ABL fusion protein, has shown particular success in therapy
of chronic myeloid leukaemia (CML) and and gastro-intestinal stromal tumours
(GIST) (Goldman and Marin, 2012; Pandey and Kochar, 2012). Other
examples are Trastuzumab, that targets the HER2/neu receptor in breast
cancer, Erlotinib and Gefitinib, two epidermal growth factor receptor (EGFR)
inhibitors, in non-small cell lung cancer (NSCLC) (Torti and Trusolino, 2011).
However, this approach is not valid for all the patients and frequently the
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benefit is of limited duration. A possible partial explanation could be found in
the heterogeneity of the cancer, especially in solid tumours. The presence of
low-frequency multiple sub-populations that are not dependent on a driver
event may, in fact, significantly influence treatment outcome in many solid
tumours (Mendelsohn, 2013; Parsons and Myers, 2013). Tumour heterogeneity
has also been found to occur in TEL-AML1 leukaemia (Anderson et al., 2011).
Analysis of the clones, however, showed that independent of the clonal
evolution and its architectural complexity, the TEL-AML1 fusion gene was
present in all the sub-clones, suggesting that these may be highly dependent
on the activity of this single oncogene for continued cell proliferation and
survival (Figure 1-10). However, transcription factors are historically avoided as
therapeutic targets because of the difficulty of developing drugs that interfere
with their binding to DNA and the associated difficulty to selectively target
nuclear biochemical events (Darnell, 2002; Konstantinopoulos and
Papavassiliou, 2011). Furthermore, even if such targeting was possible,
inhibition of transcription factor function may result in unwanted toxicity. For
example, targeting TEL or AML1 may have disrupting effects on the HSCs
compartment completely compromising haematopoiesis. From this perspective
understanding the genes and pathways controlled directly by TEL-AML1 could
help to identify new therapeutic targets that can be used for the treatment of
this particular leukaemia. Indeed the aim of the present study was to identify
specific signalling pathways regulated by the fusion gene necessary for the
survival of TEL-AML1 leukaemia. In order to achieve this we used two different
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models: mouse haematopoietic progenitor cells, in order to study the effect of
overexpression of the fusion gene, and human leukaemic cell lines carrying the
t(12;21) translocation to confirm the findings obtained with the mouse model,
with the use of commercially available selective inhibitors or/and using RNA
interference methodology.
1.4
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CHAPTER II
MATERIALS AND METHODS
2.1 Molecular biology
2.1.1 Transformation of bacteria
Sub-cloning efficiency DH5αTM, library efficiency DH5αTM and One
Shot® Stbl3™ chemically competent cells (Life Technologies – Invitrogen)
were used for transforming bacteria. At least 0.5µg of DNA was incubated in
pre-chilled polypropylene tubes (BD Bioscience) together with the competent
cells, previously thawed on ice. The mixture was incubated on ice for 30
minutes, followed by heat shock for 30 seconds in a 37̊C waterbath. The 
mixture was subsequently incubated on ice for 2 minutes and then 300µL of
SOC outgrowth medium (New England BioLabs) was added. The mixture was
then incubated in a shaker at 37̊C for 1 hour and then plated onto plates 
containing LB agar (1.5g bacto Agar (BD Bioscience) per 100ml LB broth (1%
w/v Bacto Tryptone (BD Bioscience), 0.5% w/v bacto Yeast Extract (BD
Bioscience), 1% w/v Sodium Chloride (NaCl), [pH 7.0]) and 100µg/ml Ampicillin
(Sigma-Aldrich) or 100µg/ml Carbenicillin (Sigma-Aldrich) and incubated at 37̊C 
overnight.
2.1.2 Isolation of plasmid DNA
Individual bacterial colonies were inoculated into 3ml LB broth containing the
antibiotic for the selection and incubated in a shaker at 37̊C overnight. The 
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bacterial cultures were then used to extract DNA using the PureYield™
Plasmid Miniprep System (Promega) according to the manufacturer’s
instructions. 100µl of lysis buffer was added to 600µl of bacterial culture. After
inverting the tubes 350µl of cold neutralization buffer was added and the
mixture centrifuged in a microcentrifuge at maximum speed for 3 minutes
(16000g). The supernatant was transferred to a column and centrifuged at
maximum speed for 15 seconds and the flow-through discarded. The column
was washed first with endotoxin removal buffer then with the column wash
solution containing ethanol. The plasmid DNA was eluted with 30µl of distilled
water. The DNA concentration was measured using a spectrophotometer
(NanoDrop.ND-1000, Lebtech International).
In order to obtain large quantities of plasmid DNA individual bacterial colonies
were inoculated into 3ml LB broth containing the antibiotic for selection and
incubated in a shaker at 37̊C for 6 hours. This culture was then added to 300ml 
LB broth broth containing the antibiotic for selection and incubated in a shaker
at 37̊C overnight. The genopure plasmid maxi kit (Roche) was used to isolate 
the plasmid DNA according to manufacturer’s guidelines. The bacterial culture
was centrifuged for 20 minutes at 16000g. The pellet was resuspended with
24ml for lentiviral vector DNA or 12ml for normal plasmid of resuspension
buffer and next the same volume of lysis buffer was added and incubated for 2-
3 minutes at room temperature. 12 ml of chilled neutralisation buffer was added
to the mixture, the tubes inverted 10 times and incubated for 5 minutes on ice.
The lysate was cleared by filtration and loaded onto a pre-equilibrated column.
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The column was washed 3 times with 16ml of wash buffer then eluted with pre-
warmed 15ml elution buffer. The eluted plasmid DNA was precipitated with
11ml of isopropanol and centrifuged at 4000g for 1 hour. The pellet was
washed with 70% ethanol, centrifuged for 10 minutes and air-dried. The DNA
plasmid was re-dissolved in distilled water and the concentration measured
with the NanoDrop.
2.1.3 Restriction enzyme digests
Restriction enzyme digests were performed according to the manufacturer’s
instructions. In general DNA was digested with 0.3µl or 0.5 µl of 10U/µl
restriction enzyme per µg, 10x restriction buffer and 100x BSA 10µg/µl and the
volume made up to 200µl with H20. The DNA was digested for 1-4 hours
depending on the restriction enzyme used. Depending on the size of the
fragment, the digested products were subjected to electrophoresis on 0.7-2%
w/v agarose gels [agarose (Invitrogen), 1x TAE buffer (National diagnostic),
0.5% ethidium bromide (Sigma-Aldrich)], in order to be visualised.
In order to generate fragmented DNA with a blunt end for some of the cloning
procedures, T4 DNA polymerase (Promega) was used according to the
manufacturer’s protocol. In general, 2µg of fragmented DNA was filled in with
10U of T4 DNA polymerase, 100µM of each dNTP, 10µl of 10x reaction buffer
[250mM Tris-Acetate (pH 7.7), 1M potassium acetate, 100mM magnesium
acetate and 10mM DTT] and H20 was added to make the final volume 100µl.
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The mixture was incubated for 30 minutes at 37̊C and 4µl of 0.5M 
Ethylenediaminetetraacetic acid (EDTA) was then added to stop the reaction.
2.1.4 Gel extraction
Isolated digested DNA products were purified from the agarose gel using
QIAquick Nucleotide removal kit (Qiagen) according to the manufacturer’s
guidelines. The DNA fragment was excised from the agarose gel and weighed.
A volume corresponding to three times this weight of buffer QG was added to
the excised gel and incubated at 50̊C for 10 minutes, or until the gel was 
completely dissolved. An equal volume corresponding to the weight of the gel
of isopropanol was added and the mixture was transferred onto a QIAquick
spin column and centrifuged at maximum speed for 1 minute. The column was
washed to remove any salt contamination with 0.7ml of buffer PE for 1 minute
at maximum speed, emptied and centrifuged for 1 additional minute to
completely remove ethanol contamination. DNA was then eluted by
centrifuging the column with 30µl of elution buffet.
2.1.5 Ligation
The DNA fragment and vector were ligated to generate plasmid DNA.
Depending on the cloning, the molar ratio between the fragment and the vector
varied from 1:1 to 5:1. Generally, 50ng of the vector were ligated with the
required amount of DNA fragment using 5µl of 2x Rapid Ligation Buffer [60mM
Tris-HCl (pH 7.8), 20mM MgCl2, 20mM DTT, 2mM ATP and 10% PEG]
(Promega) and 1 we
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gene for mammalian selection (puroR). ccpt, central polypurine tract; SIN/LTR,
3' self-inactivating long terminal repeat; f1 ori, f1 origin of replication; ampR:
ampicillin resistance gene for bacterial selection; pUC ori, pUC origin of
replication; 5' LTR, 5' long terminal repeat; Psi, RNA packaging signal; RRE,
Rev response element.
GENE sequence (5'-3') (sense-loop-antisense)
Non-
Mammalian
shRNA
Control
CCGG CAACAAGATGAAGAGCACCAA CTCGAG
TTGGTGCTCTTCATCTTGTTG TTTTT
ETV6
(NM_001987)
CCGG GCTGCTGACCAAAGAGGACTT CTCGAG
AAGTCCTCTTTGGTCAGCAGC TTTTT
STAT3_1
(NM_003150)
CCGG GGCGTCCAGTTCACTACTAAA CTCGAG
TTTAGTAGTGAACTGGACGCC TTTTTG
STAT3_2
(NM_003150)
CCGG GCACAATCTACGAAGAATCAA CTCGAG
TTGATTCTTCGTAGATTGTGC TTTTT
MYC_1
(NM_002467)
CCGG CCTGAGACAGATCAGCAACAA CTCGAG
TTGTTGCTGATCTGTCTCAGG TTTTTG
MYC_2
(NM_002467)
CCGG CCTGAGACAGATCAGCAACAA CTCGAG
TTGTTGCTGATCTGTCTCAGG TTTTTG
ARHGEF4
(NM_015320)
CCGG CCTCCATGTGAGCATCAAGAA CTCGAG
TTCTTGATGCTCACATGGAGG TTTTTG
Table 1: shRNA sequences used in this study.
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2.1.7 Preparation of total protein lysate for western blot analysis
Cells were harvested and washed with PBS by centrifugation at 300g for 5
minutes at 4ºC. Cell pellets were lysed using 60µL of 1x RIPA (Radio-
Immunoprecipitation Assay) buffer (Cell Signaling) [20 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium
deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1
mM Na3VO4, 1 µg/ml leupeptin] per 1x106 cells. The lysate was incubated for
20 minutes in ice, vortexed for 10 seconds, sonicated for 10 seconds and
centrifugated at 16,000g for 20 minutes at 4°C. The supernatant was collected
and the total cell lysate was stored at -80°C.
For nuclear and cytoplasmic extracts the Nuclear Extract Kit (Active Motif) was
used according to the manufacturer’s instructions. In brief, at least 1x107 cells
were harvested and washed with phosphate buffered saline (PBS) by
centrifugation at 300g for 5 minutes at 4ºC. Cell pellets were lysed using 500µl
1X hypotonic buffer and incubated for 15 minutes on ice. 25 µl of detergent was
added to the lysate and vigorously vortexed for 10 seconds. The suspension
was centrifuged for 30 seconds at 14,000 x g in a microcentrifuge, pre-cooled
at 4ºC and the supernatant representing the cytoplasmic fraction was collected
and stored at -80°C. The nuclear pellet was resuspend in 50 µl complete lysis
buffer, vigorously vortexed for 10 seconds and incubated for 30 minutes on ice.
The nuclear lysate was then centrifuged for 10 minutes at 14,000g in a
microcentrifuge pre-cooled at 4ºC and the supernatant (nuclear fraction) was
collected into a pre-chilled microcentrifuge tube and stored at -80°C.
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Protein concentration was measured using the Bradford reagent (BioRad), by
measuring the absorbance at a wavelength of 595nm using the Ultrospec 2100
pro (Amersham Pharmacia Biotech) spectrophotometer.
The NuPAGE system from Invitrogen was used to perform protein gel
electrophoresis (NuPAGE® Novex® 10% Bis-Tris Gels were used for most of
the analyses, whereas NuPAGE® Novex® 8% Bis-Tris Gels were used for
TEL-AML1 analysis and NuPAGE® Novex® 4-12% Bis-Tris Gels were used for
RAC1 analysis). Following electrophoresis, samples were transferred onto a
polyvinylidenefluoride (PVDF) membrane (Millipore) for 3 hours at 400 mA at
4ºC in a Tris-glycine-methanol transfer buffer [25mM Tris (Sigma-Aldrich),
192mM glycine (Sigma-Aldrich), 20% methanol].
2.1.8 Western blot analysis
Membranes were blocked in PBS with 5% non-fat milk and 0.2% Tween-20,
and stained with one the antibodies listed in Table 2. Proteins were detected
using the secondary antibodies conjugated with horseradish peroxidise listed in
Table 3 and a chemiluminescent reagent (ECL, GE Healthcare) or SuperSignal
West Pico Chemiluminescent Substrate (Thermo Scientific), according to the
manufacturer’s instructions. The membrane was stripped using Restore™
Western Blot Stripping Buffer (Thermo Scientific) for some experiments for 10
minutes at room temperature and re-probed with different primary and
secondary antibodies.
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Exposed film was developed using the Xograph CompactX4 (BioRad)
developer. The film was then acquired using a calibrated densitometer (GS-
800, BioRad) and individual bands were quantified using QuantityOne software
(BioRad). The relative protein expression was obtained by dividing the density
values of the protein of interest by the density values of the appropriate loading
control.
Name of antibodies Supplier Dilution
STAT3 (clone 79D7) Cell Signaling Technology 1:1000
STAT3 Y705 Cell Signaling Technology 1:500
STAT3 S727 Cell Signaling Technology 1:500
GAPDH (v-18) Santa Cruz Biotechnology 1:1000
HSP90 (F-8) Santa Cruz Biotechnology 1:1000
TEL (N-19) Santa Cruz Biotechnology 1:500
TEL (C-214) Santa Cruz Biotechnology 1:500
HLH-TEL
Kind gift of Jan Cools
(University of Leuven, Belgium)
1:1000
cleaved CASPASE 3 (5A1) Cell Signaling Technology 1:500
MYC (9E10) Santa Cruz Biotechnology 1:500
p21 (F-5) Santa Cruz Biotechnology 1:500
p27 (C-19) Santa Cruz Biotechnology 1:500
LAMIN B Santa Cruz Biotechnology 1:1000
RAC1 Thermo Scientific 1:1000
SURVIVIN (D-8) Santa Cruz Biotechnology 1:1000
AML1 Santa Cruz Biotechnology 1:500
Table 2: Primary antibodies used for western blot analyses in this study.
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Name of antibodies Supplier Dilution
anti-mouse IgG HPR-linked
whole antibody
GE HealthCare 1:3000
anti-rabbit IgG HPR-linked
whole antibody
GE HealthCare 1:5000
anti-goat IgG HPR-linked
whole antibody
Santa Cruz Biotechnology 1:5000
Table 3: Secondary antibodies used for western blot analyses in this
study.
2.1.9 RAC1-GTP pull down
RAC1 activity was detected by measuring the quantity of RAC1-GTP complex
in the cells using the Active Rac1 Pull-Down and Detection Kit according to
manufacturer’s instructions (Thermo Scientific). Cells were washed with ice-
cold tris-buffered saline (TBS) and the pellet was resuspended with 500µl
Lysis/Binding/Wash Buffer [100mL, 25mM Tris•HCl, pH 7.2, 150mM NaCl,
5mM MgCl2, 1% NP-40 and 5% glycerol] and incubated on ice for 5 minutes.
The lysate was centrifuged at 16000g for 15 minutes. After protein
quantification at least 500µg of total protein was transferred onto a column pre-
washed with 400µl Lysis/Binding/Wash Buffer and pre-loaded with glutathione
resin. 20µg of GST-human PAK1-PBD was also added to the column. The
reaction mixture was incubated at 4°C for 1 hour with gentle rocking and then
the column was washed three times with 400µl Lysis/Binding/Wash Buffer. The
column was eluted with 50µl of 2X SDS Sample Buffer [1.5mL, 125mM
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Tris•HCl, pH 6.8, 2% glycerol, 4% SDS (w/v) and 0.05% bromophenol blue]
with β-mercaptoethanol and stored at -20̊C. 
2.1.10 RNA isolation, cDNA preparation and quantitative Real-Time
PCR
Total RNA was isolated from the cells using the RNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions. The cells were disrupted by
adding buffer RLT, containing β-mercaptoethanol. Homogenization of the 
samples was achieved by shearing of genomic DNA using a 18G needle. One
volume of 70% ethanol was added to the samples and the mixture was
transferred into a RNeasy spin column. After centrifugation the column was
washed with 700μl buffer RW1 first and then subsequently with 500μl buffer 
RPE. The RNA was eluted with 30μl of diethylpyrocarbonate (DEPC) treated 
water and the concentration determined using a spectrophotometer (NanoDrop
ND-1000, Lebtech International).
RNA was converted into cDNA using the High Capacity RNA-to-cDNA Kit
(Applied Biosystems) according to the manufacturer’s instructions. 1µg of RNA
was converted using 1µl 20X Enzyme mix and 5µl 2X RT Buffer Mix in a total
volume of 10µl. Samples were treated with DNase (Invitrogen) prior the reverse
transcription.
Quantitative RT-PCR (qRT-PCR) was performed on isolated mRNA using
TaqMan probe based chemistry and an ABI Prism 7900HT fast Sequence
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Detection System (Life Technologies). All primer/probe sets were from Applied
Biosystems, Life Technologies except for TEL mRNA detection, for which a
previously published primer/probe set was used (Taube et al., 2004).
2.2 Cell biology
2.2.1 Cell culture and cell lines
The LinXE [Genetica, (Hannon, 2002)] and 293FT (Invitrogen) packaging cell
lines were cultured in Dulbecco’s Modified Eagle’s medium (DMEM, Invitrogen
Paisley) supplemented with 10% heat-inactivated foetal calf serum (FCS,
Sigma-Aldrich), 100U/ml penicillin (Invitrogen), 100µg/ml streptomycin
(Invitrogen) and 2mM L-glutamine (Invitrogen) (complete DMEM). LinXE cells
were maintained with 7.5µg/ml hygromycin (Invivogen). Human leukaemic cell
lines (Table 4) were cultured in Roswell Park Memorial Institute (RPMI)
medium (Invitrogen) supplemented with 10% heat-inactivated FCS, 100U/ml
penicillin (Invivogen), 100µg/ml streptomycin (Invitrogen) and 2mM L-glutamine
(complete RPMI). Mouse c-kit+Ter119- foetal liver haematopoietic progenitor
cells were cultured in complete DMEM medium supplemented with 100ng/ml
stem cell factor (SCF), 10ng/ml interleukin-7 (IL-7), 10ng/ml Fms-like tyrosine
kinase 3 (FLT-3) (all from Peprotech) and 50µM 2-mercaptoehanol (2-ME)
(Sigma-Aldrich). The human leukaemic cell lines Reh, 697, Tom-I and Sup-B15
were obtained from the German Collection of Microorgamisms and Cell
Cultures (DSMZ, Brunswick, Germany). Bel-I and Semk were the kind gift of R.
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Stam (Erasmus MC, Rotterdam, the Netherlands), and At-2 were the kind gift
of R. Panzer-Grümayer (Children's Cancer Research Institute, Vienna, Austria).
Each cell line was cultured at between 0.2-0.8x106/ml and sub-cultured every
three to four days according to the supplier’s instructions (DSMZ).
Cell line Translocation Fusion gene
Reh t(12;21) TEL-AML1
At-2 t(12;21) TEL-AML1
Tom-1 t(9;22) BCR-ABL
Sup-B15 t(9;22) BCR-ABL
Rs4;11 t(4;11) MLL-AF4
697 t(1;19) E2A-PBX1
Bel-1 t(4;11) MLL-AF4
Semk-2 t(4;11) MLL-AF4
Table 4: Human B-ALL cell lines used in this study.
2.2.2 Purification of haematopoietic progenitor cells
c-Kit+ Ter119- hematopoietic progenitor cells (HPCs) were purified from
embryonic day 12 (E12) foetal liver of C57BL/6 mice by magnetic bead cell
sorting (Miltenyi Biotec). The livers were carefully isolated and after red cell
lysis cells were stained with Ter119 PE antibody (BD Bioscence), washed and
incubated with 20µl anti-PE microbeads for 20 minutes at 4oC. TER119- cells
were isolated by magnetic separation using column type LS (Miltenyi Biotec).
The effluent was collected as the negative fraction, washed and stained with
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the c-Kit antibody (Biolegend). The cells were then incubated with 20µl anti-
APC micro-beads for 20 minutes in the fridge. c-Kit+ cells were isolated by
magnetic separation using column type MS (Miltenyi Biotec), washed and
resuspended in appropriate DMEM complete medium
2.2.3 Retroviral and lentiviral packaging cell line transfection
LinXE cells were seeded without hygromycin at a density of 0.75x106 per 10cm
petri dish (Thermo Fisher Scientific, Leicestershire, UK) three days before the
transfection for the production of retrovirus. A total of 8µg of expression vector
was incubated in 1.5ml Optimem (GIBCO) plus 36µl Lipofectamine 2000
reagent (Invitrogen) for 20 minutes at room temperature and then the DNA-
Lipofectamine 2000 complexes were added to the cells. Lipofectamine
containing medium was then replaced with 10ml of complete DMEM medium
on the second day of transfection.
For lentiviral packaging cell line transfection, 293FT cells were seeded at a
density of 0.5x106 per 10cm petri dish three days before transfection for the
production of lentivirus. For lentiviral transfection, 5µg of expression vector,
3.75µg of pCMV-PAX2 (which was kindly supplied by Professor D. Trono,
Lausanne, Switzerland) and 1.5µg of pVSV-G construct were incubated in 1ml
Optimem (GIBCO) plus 30µl MegaTran (OriGene) reagent for 10 minutes at
room temperature and then the DNA-MegaTran complexes were added to the
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cells. MegaTran containing medium was then replaced with 10ml of complete
DMEM medium on the second day of transfection.
2.2.4 Retroviral transduction of murine cell lines and lentiviral
transduction of human leukaemic cell lines
Retroviral supernatant was collected 48 hours after the transfection and
concentrated 2-fold for some experiments. The unfiltered supernatant was
cleared of cell debris by two rounds of centrifugation at 580g for 5 minutes. The
cleared virus was then aliquotted into 1.5ml eppendorf tubes and concentrated
by centrifugation using a micro-centrifuge at 16,000g for one hour at 4ºC.
Mouse c-Kit+Ter119- foetal liver haematopoietic progenitor cells were seeded at
1x104 cells per well, supplemented with 20% FCS, 100ng/ml SCF, 10ng/ml IL-
7, 10ng/ml FLT-3 and 5µg/ml polybrene (Sigma-Aldrich) and transduced in 96-
well flat bottomed plates (Thermo Fisher Scientific) by spinoculation
(centrifugation at 700g, for 45 minutes at 25 ºC). 24 hours after transduction,
100µl per well of complete DMEM with growth factors 100ng/ml SCF, 10ng/ml
IL-7, 10ng/ml FLT-3 was added. The transduced murine cells were used for
further experiments after 48, 72 or 96 hours of transduction.
For lentiviral transduction of Reh and AT-2 cells, 293FT supernatant was
cleared using Minisart 0.45µm filters (Sartorius Stedim Biotech).
Ultracentrifugation was performed to concentrate lentivirus in some
experiments. Sorvall 12ml centrifuge tubes (Thermo Scientific) were sterilized
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with 70% ethanol and washed twice with PBS prior to use. 11.5ml of filtered
virus was added to each tube and concentrated by ultracentrifugation at
18000g for 3 hours at 4̊C (Thermo Scientific, Discovery 100). The supernatant 
was discarded and the pellet was resuspended in 1.5ml of RPMI medium.
0.5x105 cells supplemented with 5µg/ml polybrene in 96-well plates, were
transduced by spinoculation at 700g, for 45 minutes at 25 ºC. 24 hours after
the transduction, 100µl per well of complete RPMI was added. 48 hours after
the transduction the cells were harvested and plated in complete RPMI
supplemented of 0.6µg/mL puromycin depending on the lentiviral vector used.
2.2.5 Primary patient samples
Informed consent was given by parents and/or guardians to use excess
leukaemic cell material remaining after diagnostic procedures, for research
purposes as approved by the Institutional Review Board of the Erasmus MC.
Patient sample purification procedures and proliferation analysis was
performed in Professor M. Den Boer’s Laboratory (Erasmus Mc, Rotterdam).
Mononuclear cells were separated by sucrose gradient centrifugation
(Lymphoprep 1.077g/ml density; Nycomed Pharma) and mononuclear cells
were collected for further processing. The percentage of leukemic cells was
increased >90% by eliminating contaminating normal lymphocytes and myeloid
progenitor cells using antibody-coated beads as previously described (Den
Boer et al., 2003). Cells were exposed to a 2-fold serial dilution series of
STAT3 inhibitor for 96 hours at 37oC in humidified air containing 5% CO2. Next,
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cells were incubated with 0.33µg/µl tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS; Promega)
and 7.5µg/ml of the electron coupling reagent phenazine methosulphate (PMS;
Sigma) for 3 hours. The amount of soluble formazan product formed by viable
cells was quantified at 490 nm absorbance on a VersaMax microplate reader.
Samples Sex Immunophenotype
age at
diagnosis
(years)
Karyotype
TEL\AML1_1 F pre-B-ALL 3
48,XX,add(19
)(?p13),-
?E,+21,+mar
1,+mar2
TEL\AML1_2 M pre-B-ALL 3
47,XY,t(12;2)
(p1?3;p11),
+21,inc[cp19]
TEL\AML1_3 F C-ALL 5
46,XX,der(1)
del(1)(p34)ad
d(1)(q2?2),de
r(9)t(1;9)(q1?
1;q1?2),der(9
)t(1;9)(p3?4;q
2),add(12)(p1
1~12),
TEL\AML1_4 F C-ALL 4 46,XX[19]
TEL\AML1_5 M pre-B-ALL 3
46,XY,5,der(5
)(q?),?11,add
(12)(p11),+m
ar[10][cp12]/4
6,XY[8]
TEL\AML1_6 F C-ALL 4
cytogenetics
failed; no
data
Table 5: Primary sample information.
77
2.2.6 Flow cytometry
Cells were washed with wash buffer (PBS supplemented with 0.05% w/v
sodium azide). Cells were pre-incubated with anti-mouse Fcγ III/II Receptor 
antibody (2.4G2; BD Biosciences) or human FcR-binding inhibitor
(eBioscience) containing stain buffer (PBS supplemented with 0.05% w/v
sodium azide and 1% w/v BSA) for 15 minutes on ice to block non-specific
binding. The cells were then stained with fluorochrome-conjugated antibodies
in stain buffer for 30 minutes on ice and washed with wash buffer prior to
analysis. Anti-mouse or human antibodies used in this study are listed in Table
4. PE conjugated streptavidin (Ebioscience) was also used to detect biotin
conjugated human CD2 antibody (Ebioscience).
For intracellular staining, human leukaemic cells were lysed and fixed in a
single step using BD™ Phosflow Lyse/Fix buffer (BD Bioscience) at 37̊C for the 
10 minutes. The cells were then permeabilized with 500µl BD™ Phosflow Perm
Buffer III (BD Bioscience) for 30 minutes on ice and stained with the
appropriate antibody according to manufacturer’s instructions (BD
Biosciences). Appropriate IgG isotype control antibodies were used.
All flow cytometry was performed on an LRSII analyser (BD Biosciences) and
the data was analysed with Summit 4.3 (Dakocytomation) or FlowJo v8.6 (Tree
Star) software.
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Name of antibodies Supplier Diluition
Mouse TER119-PE BD Bioscience 1:200
Mouse c-KIT-APC (2B8) Biolegend 1:200
Human CD10-PE (eBioCB-
CALLA)
BD Bioscience 1:5
Human CD19-APC (HIB19) human CD10-PE 1:5
Human STAT3 Y705-PE BD Bioscience 20µl
Table 6: Flow cytometry antibodies used in this study.
PE: phycoerythrin; APC: Allophycocyanin
2.2.7 Apoptosis
Apoptosis was detected using the Annexin V Apoptosis Detection Kit I
(eBioscience). Cells were washed with PBS followed by 1x Binding Buffer. The
pellet was then resuspended in 95µl of 1x Binding Buffer and 5µl of Annexin V-
APC or PE and incubated for 15 minutes at room temperature. The mixture
was washed and resuspended in 300µl of 1x Binding Buffer and 5µl of
500µg/ml 4',6-diamidino-2-phenylindole (DAPI) or Propidium iodide (PI). Cells
were then analysed by flow cytometry.
2.2.8 Cell cycle assays
Cell cycle analysis was performed using the Click-iT EdU Alexa Flour 647 Flow
Cytometry Assay Kit (Invitrogen). Cells were cultured with 10μM Click-iT® EdU 
for 1.5 hour. The cells were then harvested and fixed with 100µl of Click-iT®
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fixative for 15 minutes at room temperature. After one wash with PBS the cells
were permeabilizated with 1X Click-iT® saponin-based buffer. Click-iT®
reaction cocktail [Copper (II) sulphate (CuSO4); 1:10 Reaction Buffer Additive
(1M ascorbic acid); Fluorescent dye; TBS up to 500µl] was prepared and
added to the cells. The reaction mixture was incubated for 30 minutes at room
temperature, washed and resuspended in 500μL of 1X Click-iT® saponin-
based permeabilization and wash reagent containing 2µg Ribonuclease A
(Sigma) and 500µg/ml DAPI (Roche) or PI 1mg/ml. Cells were then analysed
by flow cytometry.
2.2.9 Dead cell removal
Apoptosis and cell cycle analysis of shRNA transduced cells was performed 48
hours after treatment with the Dead Cell Removal kit and culture of equivalent
numbers of viable cells (Miltenyi Biotec). Cells were centrifuged at 300g for 5
minutes, resuspended in 100µl of Dead Cell Removal MicroBeads and
incubated for 15 minutes at room temperature. Column type MS was prepared
by washing with 1x Binding Buffer and placed in a magnetic field of a MACS®
Separator. 500µl of 1x Binding Buffer was added to the cells and the mixture
was loaded into the column. The effluent was collected as the live cell fraction,
centrifuged at 300g for 5 minutes and resuspended with the appropriate
complete medium.
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2.2.10 Proliferation assays
Cells were cultured at a density of 5x104 cells per well in flat bottomed 96-well
plates in the presence of dimethyl sulfoxide (DMSO) or specific inhibitors.
DMSO was added at the same concentration as that present in the highest
inhibitor concentration used. CellTiter 96® Aqueous One Solution Reagent
(Promega, Madison, WI) was added to each well according to the
manufacturer’s instructions. After 96 hours in culture the cell viability was
determined by measuring the absorbance at 490nm using a 550 BioRad plate-
reader (BioRad) after 2 hours of incubation at 37 ºC.
2.2.11 Colony forming assays
For human cells, 1x104 cells infected with shRNA vectors or treated with
inhibitors were harvested, washed in PBS and resuspended in 600µl Cell
Resuspension Solution (HSC002, R&D systems). The cells were added to
2.7ml of human methylcellulose (R&D system). 600µl of this mixture was plated
into 24 multi-well plates using blunt end needles. The cells were cultured for 14
days before being cultured for an additional 2 days in the presence of 180µl of
10mg/ml 2-(P-iodophenyl)-3-(p-nitrophenyl)-5-phenyl tetrazolium chloride (INT)
in 75% ethanol, diluted 1:20 with PBS. The plate was then acquired using a
calibrated densitometer (GS-800, BioRad) and the colonies quantified using
ImageQuant TL software (GE Ealthcare).
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2.3 Animals
All mice were maintained in the animal facilities of the UCL Institute of Child
Health and experiments were performed according to United Kingdom Home
Office regulations. Xenotransplantation in this study was performed by Dr.
Owen William. 5-10 week old NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice were
used as recipients for transplantation of scramble and shRNAs transduced Reh
cells. These mice lack mature T cells, B cells, and natural killer (NK)
cells. They are also deficient in multiple cytokine signalling pathways, and they
have many defects in innate immunity. Specifically NSG mice associate the
features of the NOD/ShiltJ background, the combined immune deficiency
mutation (scid) and IL-2 receptor γ chain deficiency and have been shown to 
support greater engraftment of human haematopoietic stem cells (McDermott
et al., 2010). Mice were sub-lethally irradiated with 3 Gy using a 137 Cs γ-
irradiator and intravenously injected in the lateral tail vein with 1 x 105
transduced cells per mouse. Mice were sacrificed when they developed clinical
signs of disease and bone marrow was harvested for analysis.
2.4 Statistical analysis
Statistical analysis of survival curves was performed using the Mantel-Cox log-
rank test, and of SD by Student’s t test.
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CHAPTER III: Transcriptional TEL-AML1 regulated genes
3.1 Introduction
The use of microarray technology permits the simultaneous
measurement of the expression of many thousands of genes, yielding large
amounts of invaluable information and giving the opportunity to characterize
many different biological processes. For example, in the cancer field, this
technology is used to investigate the mechanisms by which a drug, disease,
mutation and environmental conditions affect gene expression and cell
function. In order to identify specific target genes whose expression is
deregulated by TEL-AML1, in collaboration with Dr. Mike Hubank, who runs the
ICH Gene Microarray Centre in our unit, our laboratory has used Affymetrix
GeneChip MOE 430plus2.0 arrays to compare gene expression profiles from
mouse haematopoietic progenitor cells (HPCs) expressing TEL-AML1 to those
expressing an inactive TEL-AML1 point-mutant, that has been shown to impair
DNA binding and TEL-AML1-induced self-renewal (Morrow et al., 2007;
Roudaia et al., 2009). These results were further compared to cells transduced
with empty retroviral vector. Using this approach, a number of genes that were
specifically up- or down regulated in HPCs by TEL-AML1 were identified
(Morrow et al., unpublished data).
In order to address the analysis of the transcriptional pathways involved
in TEL-AML1 function, we first decided to confirm the changes in the levels of
expression of the most interesting genes found to be up- or down-regulated in
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the microarray data. Hence, using the same cDNA as that used for the
microarray, we performed quantitative real-time PCR (qRT-PCR), a technique
endowed with higher sensitivity and reproducibility than microarray analysis,
using probes against the mRNA of the genes previously identified (Figure 3-1).
Following this analysis we decided to further investigate three genes in the list:
T-box transcription factor 2 (TBX2), E2F transcription factor 5 (E2f5) and
Leukaemia inhibitory factor receptor (Lif-R).
3.2 Results
3.2.1 TBX2 expression
TBX2 is a member of the T-box family of transcription factors and, with
TBX3, is the only mammalian T-box factor that has been shown to function as
a transcriptional repressor (Rowley et al., 2004). T-box proteins are DNA
binding transcription factors that recognize similar sequences and their
specificity in driving target gene induction or repression is hence only
determined by association with different cofactors. These factors play a key
role in cell identity maintenance during development. Moreover, recent work
has suggested that they may play a relevant role in cancer. For example, TBX3
can cooperate with MYC and RAS in cellular transformation (Carlson et al.,
2002), whereas TBX2 can suppress replicative senescence, regulating the
promoter of p21 and down regulating p19 (Arf) (Jacobs et al., 2000). In primary
human breast cancer, TBX2 has been found amplified in BRCA1- and BRCA2-
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mutated breast tumours (Sinclair et al., 2002) whereas in other cancers, such
as pancreas, liver and bladder, and in melanomas its expression has been
found upregulated (Abrahams et al., 2010; Lu et al., 2010)
Here, we show a over-expression of the Tbx2 gene in mouse HPCs
transduced with TEL-AML1 retrovirus compared to cells transduced with empty
vector or an inactive TEL-AML1 mutant, suggesting a direct role of the aberrant
fusion protein in the regulation of Tbx2 expression (Figure 3-2A).
In order to confirm the specificity of the over-expression of TBX2 in
presence of the t(12;21) translocation, we compared its expression in a panel
of different human B-ALL with different genetic alterations (Table 4). The qRT-
PCR results show that the transcript can be detected only in the cell lines in
which TEL-AML1 is present, clearly demonstrating a relationship between the
presence of TEL-AML1 and the over-expression of TBX2 (Figure 3-2B).
3.2.2 E2F5 expression
The E2F proteins form a family of transcription factors that regulate the
transition from the G1 to the S phase in the cell cycle, acting as modulators of
the retinoblastoma tumour suppressor protein (pRb), or its related proteins
p107 and p130 which are post transcriptionally regulated also by cyclin– cyclin-
dependent kinase (CDKs) complexes (Chen et al., 2009). The E2F family has
been traditionally divided into activator (E2F1–E2F3) and repressor (E2F4–
E2F8) subclasses. Specifically, it has shown that the expression of E2f4 and
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E2f5 when associated with pocket proteins and other co-repressors are able to
maintain the repression of E2F-responsive genes that promote entry into the
G1 phase of the cell cycle (Gaubatz et al., 2000). However, analysis of E2F5 in
other models suggests that it can be directly regulated by the cyclin E-Cdk2
complex and this interaction promotes cell cycle progression by recruitment of
the p300/CBP family of co-activators (Morris et al., 2000). Additionally, it has
been shown that E2F5, together with p107, acts as a transducer of
transforming growth factor beta (TGFβ) receptor signals upstream of cyclin 
dependent kinases (Chen et al., 2002). Moreover, this factor may have a direct
role in tumourigenesis since it has been found to be over-expressed in ovarian
(De Meyer et al., 2009) and breast cancer (Polanowska et al., 2000), and the
over-expression correlates with poorer clinical outcome (Umemura et al.,
2009). This variability of E2F5 function can be explained by the fact that E2F
family analysis is mostly based on the analysis of cells cultured in vitro but
lacks in vivo validation (Chen et al., 2009).
Starting from our microarray dataset, showing an over expression of
E2f5, we analysed its relative expression in a previously generated microarray
database of cDNAs derived from patients with different B-ALL subtypes (Ross
et al., 2003), the raw data being available in our lab. This analysis shows that
the gene belongs to the list of genes differentially expressed in TEL-AML1
samples compared to the other types of leukaemia (data not shown). The
expression data were further confirmed in a panel of different B-ALL cell lines
by qRT-PCR (Figure 3-3A). However, the qRT-PCR data using HPCs
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transduced with TEL-AML1 showed only a marginal over-expression of E2f5
when compared to HPCs transduced with the TEL-AML1 mutant (Figure 3-3B).
3.2.3 Leukaemia inhibitory factor receptor
The leukaemia inhibitory factor receptor gene (Lif-R) encodes the
cellular receptor for leukaemia inhibitor factor (LIF), a polyfunctional
glycoprotein whose inducible production can occur in many tissues. This
cytokine acts as a stimulus for platelet formation, proliferation of some
haematopoietic cells, bone formation, adipocyte lipid transport,
adrenocorticotropic hormone production, neuronal survival and formation,
muscle satellite proliferation (Metcalf, 2003) and, mainly, in the maintenance of
embryonic stem cells in an undifferentiated and pluripotent state (Williams et
al., 1988). The partner receptor chain for LIF-R is gp130, a signalling subunit of
the IL-6 cytokine receptor family that is responsible for the intracellular
activation of the Janus-activated kinase-signal transducer and activator of
transcription (JAK-STAT) and the mitogen-activated protein kinase (MAPK)
signalling pathways (Bauer et al., 2007). Due to the presence of gp130, LIF-R
is able to bind other cytokines, such as oncostatin M (OSM), ciliary
neurotrophic factor (CNTF) and cardiotrophin-1 (CT), and activate the same
downstream signalling pathways (Metcalf, 2003). In our mouse model of TEL-
AML1 over-expression, we found an increase in Lif-R mRNA expression
(Figure 3-4). However, we were not able to confirm the expression of the
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receptor using a conjugated antibody for flow cytometry in our TEL-AML1
human cell lines (data not shown).
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3.3 Discussion
Identification of the molecular mechanisms controlling target gene
selectivity and transcriptional control is essential to understand the function of
TEL-AML1 in leukaemia. Here we show a specific over-expression of two
genes involved in cell cycle, development and differentiation, and a gene
involved in cytokine responses resulting from the presence of TEL-AML1, both
in a mouse and human models.
Both TBX2 and E2F5 have been reported to regulate different phases of
cell cycle progression, interacting with or directly inhibiting key factors involved
in this process. Interestingly they act as regulators affecting the activity of the
retinoblastoma protein (pRb) and its related proteins, p130 and p107 (Gaubatz
et al., 2000; Vance et al., 2010), suggesting a possible role of this pathway in
TEL-AML1 leukaemia. On the other hand, they also have important activities in
several developmental processes, such us coordinating cell fate, patterning,
and morphogenesis of a wide range of tissues and organs. Their transcriptional
programs are poorly understood due to their involvement in such diverse
processes and their context dependant activities, especially in vitro.
Due to its role as a polyfunctional cytokine receptor, LIF-R can affect
many cellular mechanisms such as differentiation, survival, and proliferation.
Mouse progenitor cells transduced with a TEL-AML1 retrovirus showed an
increase in Lif-R gene expression but leukaemic TEL-AML1+ human cell lines
did not show any LIF-R protein expression. Two different reasons could explain
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this lack of expression by the human leukaemia cells. The first is that prolonged
in vitro culture of the cells may have selected for intracellular mechanisms of
signalling pathway activation, independent of cytokine signalling and therefore
LIF-R expression. The second explanation may be connected to the different
action of cytokines in the human and mouse models. Specifically, although LIF
is able to activate the same signalling pathway in the two organisms, this has a
different outcome in mouse and human embryonic stem cells failing to maintain
the pluripotent state of human embryonic stem cells (hESCs) (Daheron et al.,
2004). Additionally, we did not analyse whether TEL-AML1+ HPCs were able to
induce the autocrine expression of LIF or whether they would respond to such
production from the stromal niche. Further experiments are required in order to
determine whether deregulation of Lif-R gene expression by TEL-AML1 in
mouse HPC is an artefact of the mouse model, or has real significance for
t(12;21) leukaemia. However, deregulation of this gene may also give insight
into the wider signalling aberrations in TEL-AML1 leukaemia, something which
is investigated in the next chapter.
In summary, since the main features of TEL-AML1 leukaemia are a
block of B lymphocyte differentiation and uncontrolled proliferation, all of these
factors may play an important role in the development, maintenance and
progression of this disease
3.4
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CHAPTER IV: Role of STAT3 in TEL-AML1 leukaemia
4.1 Introduction
One method of analyzing microarray data that is very informative is
pathway analysis and many commercially available or free-software
applications for pathway analyses on microarray data are now available. Using
our dataset we decided to look at the signalling pathways affected following
overexpression of the TEL-AML1 fusion gene. Using Genespring software
analysis and Ingenuity Pathway (IPA) software analysis we found that a subset
of gene expression changes, such as altered Lif-R expression, highlighted
activation of the signal transducer and activator of transcription 3 (STAT3)
signalling pathway (Figure 4-1).
STAT3 belongs to of a family of seven transcription factors involved in
different cellular biological processes. It was described for the first time as
APRF (acute phase response factor), a DNA-binding factor activated by IL-6
and epidermal growth factor (EGF) able to induce acute-phase genes (Akira et
al., 1994; Wegenka et al., 1993; Zhong et al., 1994). Subsequently, at least in
cell culture systems, it was shown to be activated by diverse agents such as
growth factors, oncogenes, and interferons (IFNs) (Levy and Lee, 2002).
All members of the STAT family have a very similar structure. Like all
the other STAT proteins, STAT3 has an amino-terminal domain that is
necessary for the dimerization of unphosphorylated STAT3 molecules, a DNA-
binding domain, an SH2 domain involved in receptor recruitment and homo-
95
and hetero-dimerization, with another STAT3 molecule or other members of the
STAT family (Caldenhoven et al., 1996), and a C-terminus transactivating
domain (Figure 4-2A). An alternative isoform of STAT3, lacking part of the C-
terminal domain (STAT3β) due to alternative mRNA splicing, has also been 
described. This isoform was originally believed to act as a competitive
dominant negative. However, in more recent studies STAT3β has shown to be 
capable of regulating the expression of canonical STAT3 responsive genes as
well as several other distinct target genes (Caldenhoven et al., 1996; Maritano
et al., 2004; Schaefer et al., 1995; Yoo et al., 2002) (Figure 4-2B).
In order to be activated, STAT3 needs to be phosphorylated on the
critical tyrosine (Tyr705) residue by receptor or intracellular tyrosine kinases.
Phosphorylated molecules can then dimerize through reciprocal SH2 domain–
Y705 interactions and translocate into the nucleus, where the complex is now
able to bind to target sequences in specific promoters (Yu and Jove, 2004).
However, different functions for dimerization have also been reported. Besides
homo-dimerization, STAT3 can create hetero-dimers with distinct STAT
proteins, causing different effects depending on the cell type. Generally hetero-
dimers can act as sinks in order to reduce the pool of STAT proteins able to
homodimerize, they can bind new specific sequences and they can modulate
the transcriptional activity of STAT proteins by recruiting different co-activators
or co-repressors. In addition, it has been shown that pre-existing complexes
between non-phosphorylated STAT3 can be present in the cytoplasm, although
a clear function for these has not been clarified (Schroder et al., 2004).
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STAT3 contains a second phosphorylation site within its C-terminus.
Classically the phosphorylation of this serine (Ser727) residue was considered
to be a secondary event required for maximal transcriptional activity (Wen et
al., 1995). However, it has been shown that regulation of STAT3 function by
Ser727 phosphorylation can occur independently of Tyr705 phosphorylation,
suggesting that this residue may have an independent role in the regulation of
nuclear translocation and cell survival (Decker and Kovarik, 2000; Sakaguchi et
al., 2012). Moreover, unphosphorylated STAT3 molecules can regulate the
expression of genes distinct to those regulated by phosphoprylated STAT3
dimers. Although these studies are preliminary and further work is required to
elucidate the different mechanisms regulating the transcription factor activity of
STAT3, they illustrate the importance of this transcription factor in regulating
many cellular functions. However, in addition to regulating transcription, recent
evidence has also suggested important non-transcriptional functions of STAT3.
For example, STAT3 has been shown to stabilize the polymerization of
microtubules by directly binding stathmin (Ng et al., 2006), a small tubulin-
binding protein. More importantly, STAT3 has also been shown to be involved
in cellular respiration in the mitochondria by regulating the activities of
complexes I and II of the electron transport chain (Wegrzyn et al., 2009).
4.1.2 STAT3 in cancer and leukaemia
STAT3 can be activated in a wide variety of signalling pathways, and for
this reason it is able to regulate many fundamental processes necessary for the
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survival and proliferation of cells. This is evident in light of the fact that
disruption of the STAT3 gene in mice leads to early embryonic lethality
(Takeda et al., 1997). For this reason it is not surprising that STAT3 plays an
important role in oncogenesis and leukaemogenesis.
Aberrant overexpression and/or persistent activation of the protein have been
reported in the majority of human solid and haematological tumours (Yu and
Jove, 2004) (Table 7). Initial studies demonstrated that persistent activation of
STAT3 in immortalized fibroblasts causes cellular transformation and tumour
formation in nude mice (Bromberg et al., 1999). Subsequently, STAT3 function
was also associated with oncogenic transformation mediated by various
different oncoproteins, such as sarcoma viral oncogene homolog tyrosine
kinase (v-SRC), breakpoint cluster region (BCR) - Abelson, epidermal growth
factor receptor (EGFR) and rat sarcoma (RAS) (Bromberg et al., 1998; Frank
and Varticovski, 1996; Gough et al., 2009; Grandis et al., 1998). In fact,
constitutive activation of STAT3 affects the function of many factors commonly
deregulated in human cancer. For example, STAT3 has shown to bind the
promoter of the TP53 gene and inhibit its expression (Niu et al., 2005), to
regulate the expression of thymoma viral oncogene homolog (AKT) (Xu et al.,
2005) and to prolong NF-κB nuclear retention (Lee et al., 2009). Recent 
evidence also suggests a possible role for somatic STAT3 mutations in cancer.
Thus, activating STAT3 mutations have been discovered in 40% of T-cell large
granular lymphocytic leukaemia (Koskela et al., 2012).
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In conclusion, STAT3 is considered to play a fundamental role in
carcinogenesis and tumour development.
4.1.3 STAT3 inhibition
The inhibition of aberrant STAT3 activation by genetic approaches has
been shown to induce growth arrest and apoptosis of a wide range of
transformed cells in vitro (Chiarle et al., 2005; Konnikova et al., 2003; Li et al.,
2009). For this reason, STAT3 has emerged as an attractive target to inhibit
both oncogenesis and leukaemogenesis using pharmacological methods
(Figure 4-3). One strategy to obtain such inhibition is using an indirect method
to target the upstream regulators of STAT3. To this category belong agents
capable of inhibiting receptors involved in activation of STAT3 signalling, such
as the anti-CD20 antibody (Rituximab), that has been tested in non-Hodgkin’s
lymphomas (Alas and Bonavida, 2001), and the EGFR-directed antibodies
(Hynes and Lane, 2005). A alternative approach to blocking upstream
regulators of STAT3 is using specific tyrosine kinase inhibitors able to disrupt
STAT3 activation, such as JAK kinase and SRC kinase inhibitors (Ferrajoli et
al., 2007; Iwamaru et al., 2007; Pardanani et al., 2007; Warmuth et al., 2003).
However, the most specific and effective method of inhibiting the aberrant
activity of STAT3 is directly targeting one of the three functional domains (SH2
domain, DNA binding domain and N-terminal domain) of the protein in order to
block its activity (Figure 4-3). These specific inhibitors can be further classified
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into two different categories: (i) peptide and peptidomimetics; (ii) small
molecules nonpeptidic inhibitors.
The largest class of inhibitors that target STAT3 directly is represented
by inhibitors that interact with the SH2 domain, preventing the binding of the
STAT3 SHR domain to phosphotyrosine motifs in receptors and the
homodimerization of STAT3 molecules. These inhibitors block the activation of
STAT3 and silence STAT3-mediated gene transcription, causing cell growth
inhibition and apoptosis in different cancer models. On the other hand, a few
studies have also shown the efficacy of blocking cancer cell proliferation using
DNA-binding and N-terminal inhibitors of STAT3. Some platinum compounds,
for instance, have been reported to potentially block the DNA binding activity of
STAT3, whereas a category of short peptides that recognize the N-terminal
domain of STAT3 were also capable of inhibiting its activity [reviewed in
(Debnath et al., 2012; Page et al., 2011; Yue and Turkson, 2009)].
Although many STAT3 inhibitors have been developed, only a small
number have been used in clinical trials. Three of these, Pyrimethamine, OPB-
31121 and RTA 402, are currently being tested in clinical trials of
haematological cancers (http://clinicaltrials.gov). However, the data from these
trials are not publically available at present.
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4.2 Results
4.2.1 Inhibition of STAT3 induces apoptosis and a cell cycle block
In leukaemia, activation of STAT3 has been shown to play a role mainly
in Acute Myeloid Leukaemia (AML) whereas alteration of STAT5 is more
frequent in Acute Lymphoblastic Leukaemia (ALL) (Benekli et al., 2009). Based
on our microarray pathway analysis we decided to test the role of these two
factors in the context of TEL-AML1+ leukaemia, measuring the proliferation and
survival of human leukaemic cell lines in the presence of specific inhibitors. We
analysed two different cell lines carrying the t(12;21) translocation (Reh, At-2),
two with BCR-ABL rearrangement, representing a known STAT3 dependent
oncogenic rearrangement (Coppo et al., 2003) (Tom-I, Sup-B15), and three
with different genetic alterations (697, Bel-I, Semk) (Table 4). The TEL-AML1+
leukemic cell lines demonstrated a greater sensitivity to treatment with the
specific STAT3 inhibitors S3I-201, Stattic and Inhibitor VII, than the non TEL-
AML1+ leukemic cell lines, greater even than that of the BCR-ABL cells (Figure
4-4A, B and C). These inhibitors have been shown to be able to selectively
inhibit activation, dimerization, and nuclear translocation of STAT3 (Schust et
al., 2006; Siddiquee et al., 2007). In contrast, although activation of STAT5 has
previously been associated with t(12;21) leukaemia, as a consequence of
EpoR up-regulation (Torrano et al., 2011), its pharmacological inhibition did not
block the proliferation of Reh and At-2 cell lines (Figure 4-5).
In order to determine whether the sensitivity of the TEL-AML1+ cell lines
to STAT3 inhibition was due to induction of cell death or a cell cycle block, we
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evaluated the level of apoptosis and the effect on the cell cycle profile in cells
exposed to 50µM S3I-201 for 24 hours. Treatment of cells with this inhibitor
resulted in a substantial increase of apoptosis (Figure 4-6) and an almost
complete block of the cell cycle, in the G1-S phase transition (Figure 4-7). In
order to confirm these data molecularly, we analysed the level of cleaved
caspase 3, as a marker of apoptosis, and the expression of p21 and p27
proteins, as markers of cell cycle progression. Increased expression of both
p21 and p27 (Figure 4-8A) was readily detected after drug treatment, which
also resulted in augmented Cleaved caspase 3 (Figure 4-8B), confirming that
the S31-201 inhibitor induces both cell death and cell cycle arrest.
In order to further confirm the sensitivity of the TEL-AML+ cell lines to
STAT3 inhibition, we decided to silence the gene in these cells using small
hairpin RNA (shRNA) constructs. A set of 5 different shRNA targeting STAT3
was tested, from which we identified two independent hairpins capable of
reducing the expression of STAT3 by approximately 90% (Figure 4-9A and B).
STAT3 silencing resulted in induction of apoptosis and cell cycle inhibition,
similar to what we saw with the inhibitor (Figure 4-9C and D). Taken together,
these data indicate that STAT3 activity is of fundamental importance for the
proliferation and survival of human TEL-AML1+ cell lines.
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4.2.3 TEL-AML1 is able to regulate the level of STAT3
phosphorylation
Our lab has previously established a method to study the effect of over-
expressing the TEL-AML1 fusion protein in mouse foetal liver haematopoietic
progenitor cells (HPC). In brief, c-kit+ Ter119- HPC were purified from
embryonic day 13 (E13) mouse foetal livers and transduced with a retroviral
vector expressing TEL-AML1 (see material and methods). The overexpression
of the fusion gene in these cells was previously shown to promote B-
lymphocyte development, enhance self-renewal of B-cell precursors, and lead
to the establishment of long-term growth factor-dependent pre-B-cell lines
(Morrow et al., 2004). In order to examine the putative connection between
TEL-AML1 and STAT3, we decided to analyse the effect of TEL-AML1
expression on STAT3 activation in HPCs. Transduction of HPCs with TEL-
AML1 expressing retrovirus resulted in increased levels of STAT3
phosphorylation at both Y705 and S727 residues (Figure 4-10A, B and C).
To determine whether STAT3 activation was still dependent upon TEL-
AML1 expression in the human leukaemia cell lines, we decided to knock-down
TEL-AML1 expression in Reh cells. Because the second, non-mutated allele of
TEL is lost in Reh cells (Figure 4-11A), we were able to specifically target TEL-
AML1 using a shRNA directed against the 5’ part of TEL. This shRNA resulted
in silencing of TEL-AML1 RNA, as detected by qPCR (Figure 4-11B). In order
to confirm the efficacy of TEL-AML1 silencing, we also decided to measure
changes in fusion protein expression by Western blot analysis. Based on
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previously published data, we initially tested three different antibodies; two
recognizing the N-terminus of TEL and one the Runt Homology Domain (RHD)
of AML1 (Diakos et al., 2010; Gefen et al., 2010; Zaliova et al., 2011). All these
antibodies were tested using both nuclear and cytoplasmic extracts of human
leukaemic cells. Although all of these antibodies recognized a band at the
correct molecular weight for the TEL-AML1 protein, the band recognized
appeared to be non-specific, since it was also present in the lanes containing
extracts from non-TEL-AML1 leukaemic cells (Figure 4-12). The non-specific
band was still present after changing the percentage of the gels, time of
antibody incubation and the washing conditions. The specific TEL-AML1 band
was finally identified in nuclear extracts using a polyclonal antibody directed
against the helix-loop-helix (HLH) domain of TEL (king gift of Jan Cools,
Belgium). Using this antibody we confirmed that the TEL-specific shRNA
resulted in knock-down of TEL-AML1 protein in Reh cells (Figure 4-13).
Two different studies have previously investigated the effect of TEL-
AML1 silencing in human leukaemic cell lines. Zaliova et al in 2011 used siRNA
transfection to target TEL-AML1. They reported that TEL-AML1 depletion did
not alter the survival, proliferation and clonogenic potential of Reh cells, and
indeed resulted in no significant changes in gene expression in the transfected
cells (Zaliova et al., 2011). In contrast, Fuka et al in 2012 used stable shRNA
expression to demonstrate that TEL-AML1 knock-down resulted in cell cycle
inhibition and impaired engraftment of Reh cells in a xenotransplantation
mouse model (Fuka et al., 2012). Our data are consistent with the latter study,
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knock-down of TEL-AML1 with our construct resulting in a G1-S phase arrest
(Figure 4-14A) and a reduction in clonogenic activity of Reh cells in a
methylcellulose based colony-forming unit assay (CFU assay) (Figure 4-14B).
In order to consolidate the importance of the fusion gene for the survival and
proliferation of the leukemic cells, we transduced the Reh cell line with a TEL-
AML1 mutant. This mutant lacks of the the runt homology domain (RHD) and it
has been shown previously to abolish TEL-AML1 binding to RUNX1 DNA
consensus sequences (Morrow et al., 2007). Our hypothesis was that
overexpression of this mutant could act as a dominant negative mutant with
respect to TEL-AML1, binding the fusion protein through protein-protein
interactions between the respective TEL moieties. Although this hypothesis still
requires careful validation, overexpression of the mutant protein resulted in
increased apoptosis, a block in the cell cycle and reduced colony formation in
methylcellulose. These data are entirely consistent with the results from shRNA
mediated silencing of the fusion gene and highlight the importance of TEL-
AML1 for the survival of leukaemic clones (Figure 4-15A-C).
Furthermore, and confirming the link between the fusion protein and
STAT3 activity observed in mouse HPC, TEL-AML1 silencing in Reh cells
resulted in reduced levels of phosphorylated Y705-STAT3 (Figure 4-16).
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4.2.4 Activation of STAT3 is necessary for the self-renewal and
leukaemogenic activity of TEL-AML1
By definition leukaemia is a malignant disease of the blood-forming
organs, characterised by abnormal proliferation and development of leukocytes
and their precursors in the blood and bone marrow. In normal conditions,
proliferation and self-renewal of precursor cells is a process highly regulated by
networks of proto-oncogenes and tumour suppressors. In contrast, in the
malignant context self-renewal appears to be one of the main deregulated
processes, as a consequence of severe imbalances within such networks.
STAT3 has been shown to be important for self-renewal activity in
different types of cancer, such as glioblastoma and breast cancer (Dave et al.,
2012; Guryanova et al., 2011). For this reason, we decided to analyse the
clonogenic capacity of TEL-AML1+ cell lines in the presence of
pharmacological or molecular inhibition of STAT3. The ability of TEL-AML1
expressing cells to form colonies in CFU assays was specifically inhibited by
the addition of the drug S3I-201 when compared to non-TEL-AML1+ cells
(Figure 4-17), or by silencing STAT3 expression (Figure 4-18), suggesting that
blocking STAT3 activity is not only responsible for a decrease in viability of the
bulk of the cell lines, but it also inhibits their self-renewal capacity.
In order to address the importance of STAT3 in leukaemia progression
in vivo, we next transplanted immunocompromised NSG mice with Reh cells
following STAT3 silencing (Figure 4-19). Although all of the transplanted mice
developed leukaemia, the latency of leukaemia onset was significantly greater
106
in those transplanted with STAT3-specific shRNA transduced cells (Figure 4-
20A). Moreover, increased levels of STAT3 mRNA expression were detected in
the shRNA transduced cells recovered from leukaemic mice, in comparison to
those observed in the cells pre-transplantation (Figure 4-20B). This
demonstrates in vivo selection against leukemic cells with low STAT3
expression. Similar selection against cells expressing low levels of STAT3 was
also seen in long-term in vitro cultures of transduced Reh cells (Figure 4-20C
and D).
4.2.5 Human TEL-AML1+ primary leukaemia cells are sensitive to
S3I-201
In order to analyse the importance of STAT3 in primary leukaemia
samples, we collaborated with Professor Monique den Boer’s group at the
Erasmus MC institute in Rotterdam. They tested the sensitivity of four different
TEL-AML1+ primary leukaemia samples (Table 5) to different concentrations of
S3I-201. The dose response curves obtained show very similar sensitivity of
the primary leukaemia cells to that displayed by the Reh cell line (Figure 4-
21A). We obtained frozen vials of two further TEL-AML1+ primary leukaemia
samples, in order to examine their responses to STAT3 inhibition in more
detail. Although these leukaemia cells exhibited relatively high levels of
spontaneous apoptosis following in vitro culture, treatment of the cells with S3I-
201 during this culture period caused a significant increase in apoptosis (Figure
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4-21B). This data indicates that TEL-AML1+ primary leukaemia cells are also
highly dependent on STAT3 activity.
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4.3 Discussion
The molecular pathways regulated by TEL-AML1 remain largely
unknown. Here we present evidence for the novel role of STAT3 signalling in
the maintenance of TEL-AML1 driven leukaemia.
Mouse progenitor cells transduced with a TEL-AML1 expressing
retrovirus showed an increase in phosphorylation of STAT3 whereas knock-
down of the fusion gene in human TEL-AML1+ leukemic cell lines resulted in
reduced levels of phospho-STAT3. Taken together, these results demonstrate
a role for TEL-AML1 in regulating the activity of STAT3. Moreover, human
leukaemic cell lines carrying this translocation exhibited increased sensitivity to
STAT3 inhibition, especially with S3I-201, in comparison to leukaemic cells
containing distinct genetic aberrations. STAT3 inhibition with S3I-201 and two
independent shRNA constructs, resulted in apoptosis, cell cycle arrest and
impairment of the clonogenic activity of TEL-AML1+ cells. Furthermore our data
indicate that STAT3 is important for the progression of leukaemia in an in vivo
experimental model and, more importantly, for the survival of primary patient
leukaemia cells.
Although STAT5 rather than STAT3 has been previously associated with
ALL, treatment of TEL-AML1+ human cell lines with a STAT5 inhibitor did not
affect their proliferation. This suggests that at least in vitro this factor is of minor
importance in TEL-AML1 leukaemia. STAT3 function on the other hand has
been implicated in AML rather than ALL pathogenesis and despite it being a
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well-studied transcription factor, little is known about its function during the B-
lymphocyte development. Recent work has suggested a possible role for
STAT3 in early B cell development, probably acting at the pre-pro B transition
by contributing to the survival of IL-7 responsive progenitors (Chou et al.,
2006). Thus, IL-7 has been shown to increase the activity of STAT1, STAT5
and STAT3 in B progenitor cells, thereby regulating the survival and the
proliferation of these cells (van der Plas et al., 1996) but not of mature B cells
(Henney, 1989). Furthermore, IL-7 receptor (IL-7R) gain-of-function mutations,
causing constitutive activation of STAT and mTOR pathways, have been
reported in paediatric B-ALL (Shochat et al., 2011). However, although IL-7R
signalling may explain STAT3 activation in the B cell progenitor pool
susceptible to transformation by TEL-AML1, a study demonstrating
suppression of IL-7R expression upon expression of this fusion gene in mouse
bone marrow cells suggests that this pathway is unlikely to play an important
role in STAT3 activation in TEL-AML1+ leukaemia (Tsuzuki et al., 2004).
Similar to the results obtained with TEL-AML1+ cell lines, we also
demonstrated a high sensitivity of BCR-ABL+ ALL cell lines to STAT3 inhibition.
In ALL, this fusion has been associated with constitutive activation of STAT5,
even though, there is evidence that BCR-ABL is able to activate other
members of the STAT family (Ilaria and Van Etten, 1996) in distinct
haematopoietic diseases, such as chronic myeloid leukaemia (CML) (Coppo et
al., 2003). Our data suggest that activation of STAT3 is not exclusive to TEL-
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AML1+ ALL and that STAT3 may be a therapeutic target in different subtypes of
ALL, as well as in AML.
ETV6 has been shown to repress the transcriptional activity of STAT3
(Schick et al., 2004) whereas, in contrast, RUNX1 has a synergistic effect with
STAT3 in gene transcription activation (Yanagida et al., 2005). The genes
encoding these transcription factors, besides being involved in the TEL-AML1
translocation itself, also represent two of the most frequent targets of
secondary alterations in TEL-AML1+ leukaemia. Specifically, ETV6 is lost in
more than 60% of the cases (Kempski and Sturt, 2000) whereas increases in
RUNX1 copy number occur in almost 25% of the cases (Chung et al., 2010).
For this reason secondary mutations, such as loss of the wild-type ETV6 allele
and acquisition of additional RUNX1 copies, may be progressive due their
effects on the transcriptional regulation of STAT3 target genes.
It is unclear how TEL-AML1 deregulates STAT3 activation. One
possible way in which this could be achieved would be via interaction between
the fusion protein and STAT3 in the nucleus, through direct binding or via co-
factors such as Sin3a, which has been shown to bind both TEL-AML1 and
STAT3 (Icardi et al., 2012). Another possibility is transcriptional deregulation by
TEL-AMl1 of intracellular factors able to activate STAT3 or, in vivo, of particular
cytokines or growth factors capable of inducing STAT3 signalling.
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In conclusion we showed for the first time an aberrant STAT3 activation
that is necessary for the survival, proliferation and self-renewal of TEL-AML1+
ALL.
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4.4 Figures
Figure 4-1: Network analysis of TEL-AML1 target gene expression.
The diagram shows the analysis of networks of genes down- or up-regulated in
HPCs transduced with a TEL-AML1 retroviral vector, after normalization to
TEL-AML1 mutant and control empty vector (see section 3.1). The analysis
revealed that one of the main common factors altered, after combining all the
pathways, was STAT3. The figure indicates that some targets of TEL-AML1,
shown in red (up-regulated) and green (down-regulated), may also be directly
regulated by STAT3. In order to facilitate comprehension of the figure all the
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genes up- or down-regulated that are responsible, upstream or downstream, of
the regulation of the pathways indicated and are not directly linked to STAT3
have been removed.
Figure 4
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Figure 4-4: Pharmacological inhibition of STAT3 leads to a specific block
of proliferation in human TEL-AML1+ cell lines.
The chart shows the proliferation of leukaemic cell lines as measured by MTS
assay after 96 hours culture with the indicated concentrations of the following
STAT3 inhibitors: S3I-301 (A), Stattic (B) and Inhibitor VII (C). Results are
normalized to the proliferation of DMSO treated cells. All data are
representative of three independent experiments and show means ± s.d. of
triplicate measurements.
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Figure 4-5: STAT5 inhibition does not affect TEL-AML1+ cell line
proliferation.
The chart shows the proliferation of leukemic cell lines as measured by MTS
assay after 96 hours culture with the indicated concentrations of STAT5
inhibitor (STAT5in). Results are normalized to the proliferation of DMSO
treated cells. All data are representative of three independent experiments and
show means ± s.d. of triplicate measurements.
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Figure 4-16: STAT3 Y705 level is reduced as consequence of TEL-AML1
silencing.
The image shows FACS analysis of p-Y705 STAT3-PE in Reh 6 days after
transduction with control scramble (MFI=21.04) or shTA (MFI=12.01) shRNA.
Isotype control staining (MFI=10.23) is also shown. All data are representative
of three independent experiments.
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CHAPTER V: RAC1 regulates STAT3 activity in TEL-AML1
leukaemia
5.1 Introduction
5.1.1 How is STAT3 activated in t(12;21) ALL?
Cell survival, cell proliferation and cell differentiation are often regulated
by extracellular factors that can be grouped into three different categories:
cytokines, hormones and growth factors. Cell surface receptors can be
activated by all three of these different elements and can mediate signals from
the extracellular environment to the nucleus, coordinating responses through
different molecular signalling networks. Several of these signal transduction
cascades culminate in the activation of STAT proteins. Classically, ligand
induced receptor activation causes STAT binding to phosphotyrosine residues
of the stimulated membrane receptor, through their SH2 domains, and
subsequent tyrosine phosphorylation of the STAT proteins by the receptor itself
or by associated kinases.
There are many ligands capable of activating STAT proteins. Some,
such as the epidermal growth factor (EGF), platelet-derived growth factor
(PDGF), and colony-stimulating factor–1 (CSF1) are ligands for receptors with
intrinsic tyrosine kinase activity. In contrast, others bind receptors that lack
intrinsic tyrosine kinase activity but are capable of binding to Janus kinases
(JAKs) that are responsible for STAT protein activation. This is the case for the
large haematopoetin subfamily of cytokines that includes the interferons (IFN-α, 
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-β and –γ) and interleukins 2-7, 10-13, 15, 19-24, 27 and 35 (Darnell, 1997; 
Schindler and Plumlee, 2008). Binding of these cytokines to their receptors
leads to the activation of JAKs, which then phosphorylate themselves and the
bound receptors at specific tyrosine residues which can be recognized by the
SH2-domains of STAT proteins, or other SH2-containing adaptor proteins
(Imada and Leonard, 2000).
TEL-AML1+ leukaemia cells have never been associated with a
dependence upon particular growth factors or cytokines for their proliferation,
and there have been no reports of growth factor over-expression thus far.
There are, however, several alternative mechanisms that could account for
STAT3 activation in t(12;21) ALL, such as intracellular overexpression of
mediators of STAT3 signalling.
5.1.2 JAK2 and STAT3 activation
The JAK family has four different members: JAK1, JAK2, JAK3 and
Tyrosine kinase 2 (TYK2) (O'Shea et al., 2004). All the members are
fundamental to modulate and mediate extracellular signals into the cell.
However, knock-out studies suggest they have non-overlapping functions.
Thus, although JAK1-deficient and JAK2-deficient mice die prenatally, the latter
due to profound anaemia (Sansone and Bromberg, 2012), JAK3-deficient and
TYK-2-deficient mice are viable, exhibiting haematopoietic defects in lymphoid
development and impaired cytokine responsiveness, respectively (Karaghiosoff
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et al., 2000; Nosaka et al., 1995; Thomis et al., 1995). All the proteins of this
family have seven domains (JH1-JH7), including a FERM (a band four-point-
one, ezrin, radixin, moesin) domain for cytokine receptor interaction, an SH2
domain for protein interaction, a C-terminal kinase domain (JH1) and a
pseudokinase domain (JH2). In order to transmit signals from the outside of
the cell to the nucleus, JAK proteins need to be activated by auto-
phosphorylation at specific tyrosine residues. This phosphorylation is triggered
by ligand-induced conformational changes in receptors, resulting in
juxtaposition of receptor-bound JAK molecules. These then activate each other
by trans-phosphorylation, and subsequently phosphorylate the ligand-bound
receptors and downstream targets, such as the STAT proteins. One of the
main JAK family members responsible for STAT3 activation in different models
and cancers is JAK2 (Behera et al., 2010; Marotta et al., 2011).
Constitutive activation of the JAK/STAT pathway has been described in
many diseases and particularly in haematological cancers. JAK2 mutations that
cause constitutive STAT protein activation, and thereby confer growth factor-
independent proliferation of malignant clones, are frequent in myeloproliferative
neoplasms (Kralovics et al., 2005). They have been identified also in B-cell
ALL, particularly when this is associated with Down’s syndrome (Mullighan et
al., 2009). In this context, mutations of JAK2 are often associated with
overexpression of the CRLF2 receptor that leads to an even more powerful
activation of the JAK-STAT pathway (Harvey et al., 2010). Additionally, in some
patients with T-cell ALL, pre-B-cell ALL and atypical CML, JAK2 has been
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shown to be involved in the formation of a fusion protein with TEL, which is
responsible for the constitutive activation of STAT1, STAT3 and STAT5
(Lacronique et al., 1997).
5.1.3 Intracellular activation of STAT3: the role of RAC1
As previously mentioned, besides JAK-mediated activation, STAT3 can
also be phosphorylated by different cytoplasmic tyrosine kinases and by
growth-factor receptors that have intrinsic tyrosine-kinase activity. The first
category includes SRC-related kinases, Abelson leukaemia protein (ABL) and
c-Fes protein, whereas epidermal growth factor receptor (EGFR), platelet-
derived growth factor receptor (PDGFR) and hepatocyte growth factor (HGF)
all belong to the second. Recent evidence indicates that members of the small
Rho GTPase family are also able to activate STAT3. The Rho (Ras
homologous) proteins are a subgroup of the Ras small GTPase superfamily
that differ from the other members of the family by the presence of a Rho-
specific insert in the GTPase domain. More than twenty Rho GTPases have
been described but only 3 members, RhoA, Rac1 and Cdc42 are ubiquitously
expressed. The main function of these proteins is the regulation of cytoskeleton
remodelling and they are all involved in actin polymerization, cell polarization,
motility and adhesion. In addition, they also function in cell growth, apoptosis,
cell cycle progression and genomic stability (Bokoch, 2000). For these
reasons, deregulation of their expression can play a role in oncogenesis and
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tumour progression. Thus, increases in the levels of Rho family proteins have
been observed in a number of cancers (Karlsson et al., 2009).
There are three different isoforms of the RAC subfamily that are
differentially expressed: RAC1, RAC2 and RAC3. RAC1 and RAC3 are more
widely expressed than RAC2, which is restricted to cells of haematopoietic
origin. The most studied factor of the family is RAC1 and it has emerged as a
fundamental upstream activator of multiple signaling pathways regulating gene
expression, including STAT3. However, the mechanisms by which RAC1 is
able to activate STAT3 remain unclear. Some studies suggest that RAC1
activates STAT3 directly, reporting binding between the two proteins (Simon et
al., 2000), but evidence also exists for indirect induction via IL-6/JAK signaling
(Debidda et al., 2005; Faruqi et al., 2001). RAC1 has also been shown to form
a complex with STAT3 and MgcRacGap, a RAC1 GTPase activating protein.
This association was shown to be required for STAT3 phosphorylation and
nuclear translocation (Kawashima et al., 2006; Tonozuka et al., 2004) (Figure
5-1).
5.1.4 Regulation of RAC1 activity
The activity of RAC1 is mainly regulated by two groups of proteins,
called Guanine nucleotide exchange factors (GEFs) and GTPase-Activating
Proteins (GAPs). The proteins belonging to these two families are able to
regulate the GTP/GDP cycle and consequently the levels of active and inactive
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RAC1 within the cell. Furthermore, the activity of RAC1 is also negatively
regulated by another group of proteins, specific for the RHO GTPase family,
called Guanosine nucleotide dissociation inhibitors (GDIs) (Figure 5-2).
RAC1 activation is mediated by GEF proteins, which are responsible of
converting the inactive GDP-bound form of RAC1 to the active GTP-bound
form. The latter is able to interact with specific effectors, such as p21 activating
kinases (PAK) (Frost et al., 1996; Manser et al., 1994) and MLK2/3 (Teramoto
et al., 1996), and in this way to coordinate the activation of a multitude of
signaling pathways that regulate different cellular processes. Most of the GEFs
able to activate RAC1 are characterized by a Dbl-homology (DH) domain, that
is responsible of the catalytic activity of the proteins, and a pleckstrin homology
(PH) domain, which affects the activity of the DH domain and is responsible for
the localization of the GEF proteins to the plasma membrane, through lipid
binding (Karnoub et al., 2001). The activity of some of the GEF proteins
appears to be highly specific towards a single GTPase, whereas others are
reported to be able to activate several GTPases. Moreover, differences have
also been reported between in vitro and in vivo GEF specificities (Schmidt and
Hall, 2002). GEF activation is tightly regulated through three different
mechanisms: relief of intramolecular inhibitory sequences by allosteric
modification induced mainly by phosphorylation, stimulation and inactivation by
protein-protein interactions, and alteration of intracellular localization (reviewed
in (Schmidt and Hall, 2002)).
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In contrast, GAP proteins function by terminating the signalling event
through increasing the rate of GTP hydrolysis and consequent conversion of
GTP-bound to GDP-bound GTPase. However much less is known about this
process. Additionally, the proteins of the Rho family are negatively regulated by
the action of Rho guanine nucleotide dissociation inhibitors (Rho-GDIs)
(Mackay and Hall, 1998). These proteins regulate GTPase signalling by three
different mechanisms: they can prevent nucleotide dissociation and GDP/GTP
exchange to antagonize GEF activity, interfere with GTP hydrolysis and
stimulate the release of Rho GTPases from the membrane, where they are
active, into the cytosol (Karnoub et al., 2004).
5.2 Results
5.2.1 Analysis of JAK2 in TEL-AML1 leukaemia.
Based on the association of JAK2 with STAT3 activation in the literature,
we decided to examine whether JAK2 was responsible for the constitutive
activation of STAT3 in TEL-AML1 leukaemia. We tested the JAK2 inhibitor
AG490 on our panel of pre-B cell lines, in a similar assay to that used to
demonstrate the inhibitory activity of S3I-201. However, in contrast to S3I-201,
AG490 did not have any inhibitory effect on the proliferation and survival of
TEL-AML1+ cells. In contrast, the BCR-ABL+ TOM-1 cells exhibited sensitivity
to JAK2 inhibition, as previously reported (Deininger et al., 1997). These data
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suggest that an alternative pathway may be responsible for STAT3 activation in
TEL-AML1 leukaemia (Figure 5-3).
5.2.2 Role of RAC1 in TEL-AML1 leukaemia
Based on the evidence that RAC1 is a mediator for the activation of
STAT3 and that Reh cell lines were shown to be highly sensitive to RAC1
pharmacological inhibition (Troeger, 2010), we decided to examine whether the
activation of STAT3 observed in TEL-AML1 leukemia could be mediated by
RAC1.
For this purpose we measured the level of Tyr705 STAT3 in Reh and At-
2 cells six hours after treatment with the RAC1 inhibitor NSC 23766. This
inhibitor acts by blocking the binding of RAC1 protein to the specific activating
GEFs TrioN and Tiam 1 (IC50 = 50 μM) showing no effect on the closely related 
GTPases, Cdc42, and RhoA (Gao et al., 2004). Both Western blot (Figure 5-
4A) and flow cytometric analysis (Figure 5-4B) demonstrated a dose-
dependent inhibition of Tyr705 STAT3 phosphorylation in response to NSC
23766, suggesting a role for RAC1 in regulating the activation of STAT3 in
these cells. In addition, in order to assess the importance of RAC1 for the
survival of TEL-AML1+ cells, we measured the level of apoptosis and cell cycle
progression after NCS 23766 treatment. Exposure of both TEL-AML1+ human
leukaemic cells to 50µM of the compound for 24 hours resulted in induction of a
similar percentage of cell death (Figure 5-5A) and cell cycle block (Figure 5-5B)
145
to that observed with the STAT3 inhibitor S3I-201. We showed previously, that
TEL-AML1 is capable of activating STAT3 in mouse HPC. In order to determine
whether RAC1 induction was similarly dependent on TEL-AML1, we examined
RAC1 activity in mouse HPC following transduction with the fusion gene.
Indeed, TEL-AML1 overexpression resulted in a marked increase in the levels
of GTP-RAC1 present in the cells (Figure 5-6A). Furthermore, this dependence
was conserved in human leukaemia cells. Silencing of fusion gene expression
in Reh cells, using the shRNA against TEL, also resulted in reduced GTP-
RAC1 levels (Figure 5-6B).
Taken together, these data suggest a role for TEL-AML1 in regulating
the activity of RAC1, which in turn induces STAT3 activation.
5.2.3 RAC1 activation is mediated by ARHGEF4 in TEL-AML1
leukaemia
Activation of RAC1 in TEL-AML1 leukemia cell lines has been reported
also by other groups (Holland et al., 2011). However, how this activation is
achieved has not yet been clarified. One possible mechanism could be via up-
regulation of RAC1-specific guanine nucleotide exchange factor (GEF)
expression. A recent study from our group showed that the RAC1/CDC42 GEF
ARHGEF4 (ASEF) is specifically associated with TEL-AML1 (Lyons et al.,
2010) in gene expression datasets of childhood acute leukaemias (Haferlach
et al., 2010; Ross et al., 2003; van Delft et al., 2005) (Figure 5-7). This GEF
was ﬁrst identiﬁed by Thiesen et al. from a human neuronal teratocarcinoma 
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library screen (Thiesen et al., 2000). Subsequently, ARHGEF4 was found to be
regulated by the Adenomatous polyposis coli (APC) protein and hence became
more commonly referred to as ASEF (APC-stimulated guanine exchange
factor). There are two transcripts of the ARHGEF4 gene. The two isoforms
have identical sequences, apart from an additional exon in the long isoform,
encoding additional C-terminal amino acids that do not contribute to the known
functional domains (Thiesen et al., 2000).
The association of elevated ARHGEF4 expression with t(12;21) ALL
suggested that this gene may be a transcriptional target of TEL-AML1. In order
to examine this possibility, we analysed ARHGEF4 expression following
silencing of fusion gene expression. Indeed, knock-down of TEL-AML1 in
human cell lines resulted in reduced levels of ARHGEF4 expression,
suggesting that TEL-AML1 does regulate the expression of this GEF in human
leukaemia cells (Figure 5-8). In order to examine whether ARHGEF4 regulates
the activity of RAC1 in these cells, we measured the levels of GTP-RAC1 in
Reh cells three days after shRNA-mediated silencing of ARHGEF4 gene
expression. Despite only achieving moderate silencing of ARHGEF4, this was
sufficient to cause a significant reduction in the activity of RAC1 (Figure 5-9A
and B). This reduction, moreover, resulted in decreased levels of Tyr705
STAT3, confirming our previous data that indicated a dependence of STAT3
phosphorylation on RAC1 activity in TEL-AML1+ leukaemia (Figure 5-9C). In
addition, ARHGEF4 silencing in Reh cells resulted in almost complete cell
death after 5 days (Figure 5-10A) and abrogation of their ability to form
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colonies in methylcellulose (Figure 5-10B). Finally, we decided to transplant
NSG mice with Reh cells silenced for ARHGEF4. We injected the cells three
days after transduction with shRNA, thus keeping the resultant apoptosis
induction to a minimum, allowing us to compare engraftment with equivalent
numbers of viable control and ARHGEF4-silenced cells. None of the mice
transplanted with Reh cells deficient for ARHGEF4 expression developed
leukaemia. In contrast, mice transplanted with an equivalent number of viable
scramble-shRNA transduced Reh cells all succumbed to leukaemia (Figure 5-
11). These data indicate that ARHGEF4 expression is critical for the in vivo
engraftment of TEL-AML1+ cells, and suggest that this GEF plays a
fundamental role in the progression of TEL-AML1+ ALL.
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5.3 Discussion
As already mentioned, the aberrant activation of STAT3 associated with
numerous different cancers can be achieved in many different ways. Here we
show that in TEL-AML1+ leukaemia this activation is induced mainly by RAC1.
Although RAC1-mediated STAT3 activation has previously been reported in a
number of different studies, the mechanism remains unclear. Some studies
have reported that RAC1 activates STAT3 directly, but evidence also exists for
indirect induction via interleukin 6 signalling. The insensitivity of TEL-AML1+
cell lines to JAK2 inhibition in our experiments suggests that the activation of
STAT3 by RAC1 in these cells is likely to occur through a direct intracellular
mechanism. However, other intracellular kinases, such as other JAKs or SRC
and SYK family members, could also be responsible for STAT3 activation, in
cooperation with or independent of RAC1. Further experiments are therefore
required in order to clarify the mechanisms underlying STAT3 activation in
these cells.
RAC1 plays an important role in haematopoiesis and normally is
coexpressed with RAC2 in cells of haematopoietic origin. This coexpression is
likely to result in a degree of functional redundancy, with potentially overlapping
functions (Weston and Stankovic, 2004). Analysis of TEL-AML1+ cell lines,
however, did not reveal any significant RAC2 activity, although primary
samples were not analysed in this study, suggesting a unique role for RAC1 in
this subtype of leukaemia (Holland et al., 2011). Activity of RAC1 is mainly
modulated by GEFs and GAPs, which are able to regulate the transition
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between the inactive GDP-bound form to the active GTP-bound state and vice
versa. Alterations in the function of these factors, has been demonstrated to
play a role in cancer development (Vigil et al., 2010). In contrast to the RAS
GEF family, no point mutations have been reported in the RHO GEF family.
However, their overexpression has been implicated in the growth of several
cancers. In addition, two RHO GEFs are structurally mutated in leukaemia by
chromosome rearrangement, giving rise to the mixed-lineage leukemia (MLL) -
ARHGEF12 (Kourlas et al., 2000) fusion protein and BCR-ABL1 fusion protein
(Sahay et al., 2008), both of which retain the ability to activate RHO proteins. In
contrast to the many GEFs reported to be altered in cancer, much less is
known about GAPs. The best characterized example is the tumour suppressor
role for ARHGAP7 in many cancers (Lahoz and Hall, 2008). Deregulated GEF,
GAP or GDI gene expression would be expected to contribute to the aberrant
activation of RAC1 in cancer. Indeed, here we show that expression of the
RAC1-specific GEF ARHGEF4 is associated with TEL-AML1 leukaemia and its
elevated expression is responsible for RAC1 activation. However, ARHGEF4
silencing resulted in only partial reduction in the activity of STAT3, suggesting
that alternative pathways may also be involved in STAT3 activation in these
cells. On the other hand, ARHGEF4 silencing resulted in complete loss of cell
viability. Indeed, the effect of losing expression of this GEF was even more
pronounced than that resulting from STAT3 and RAC1 inhibition, suggesting
that it may regulate additional signalling cascades critical for survival of TEL-
AML1 leukaemia cells. However, identification of these cascades is
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complicated by the limited number of studies that have addressed ARHGEF4
function. ARHGEF4 has been described as an important mediator of APC
function, playing a role in the migration of colorectal tumour cells, expressing
truncated APC (Kawasaki et al., 2003). It has also been shown to act as a
downstream effector of hepatocyte growth factor (HGF) and
phosphatidylinositol 3-kinase (PI3K) signalling (Kawasaki et al., 2003;
Kawasaki et al., 2009). This may suggest that in TEL-AML1, these two factors
play a role in stimulating ARHGEF4 activity, triggering additional signalling
pathways independent of STAT3 activation.
Classically, as mentioned in the introduction, TEL-AML1 has been
considered to be a transcriptional repressor. Some groups suggested a
dominant-negative function of this fusion on RUNX1 target genes, similar to
that observed with AML1-ETO (Zelent et al., 2004). Recent findings, however,
have shown that TEL-AML1 may also activate gene expression, promoting the
transcription of genes, bound by RUNX1 in normal haematopoiesis (Fuka et al.,
2011). In a previous report, we showed that ARHGEF4 can co-operate with
TEL-AML1 in promoting mouse B cell progenitor colony formation (Lyons et al.,
2010). However, TEL-AML1 did not appear to regulate Arghef4 gene
expression in these mouse B cell progenitors. In contrast, here we show that
expression of ARHGEF4 is strictly dependent on the presence of TEL-AML1 in
human cell lines. It remains unclear whether this is caused by direct binding of
TEL-AML1 to ARHGEF4 promoter sequences or via deregulation of
downstream transcriptional regulators. The difference between the experiments
151
in mouse B cell progenitors and human leukaemia cells may be due to
differences in regulation of gene expression by haematopoietic transcription
factors in mouse and human cells. Indeed, recent genome-wide chromatin
immunoprecipitation (ChIP) analyses demonstrated binding of RUNX1 to
ARHGEF4 promoter elements in human megakaryocytes (Tijssen et al., 2011)
but not in mouse HPCs (Wilson et al., 2010). Since the RUNX1 DNA-binding
domain is retained in the TEL-AML1 fusion protein, this suggests that
ARHGEF4 may be a direct transcriptional target of TEL-AML1 in human cells
but not in mouse haematopoietic progenitor cells. This would further indicate
that the TEL-AML1 fusion protein can function as a transcription factor able to
promote the expression of genes necessary for leukaemic transformation and
progression.
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Figure 5-3: JAK2 inhibition does not affect proliferation of TEL-AML1+
leukaemic cell lines.
The chart shows the proliferation of leukemic cell lines as measured by MTS
assay after 96 hours culture with the indicated concentrations of a JAK2
inhibitor (AG490). Results are normalized to the proliferation of DMSO treated
cells. All data are representative of three independent experiments and show
means ± s.d. of triplicate measurements.
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Figure 5-7: Expression of ARHGEF4 is specifically associated with
t(12;21) leukaemia [Adapted from https://www.oncomine.org].
The figures show the specific association of elevated ARHGEF4 expression
with the presence of the TEL-AML1 rearrangement, after analysis of microarray
expression datasets of childhood acute leukaemias. Two independent studies
demonstrated that the expression of ARHGEF4 is higher in TEL-AML1
leukaemia compared to other subtypes of ALL (Haferlach et al., 2010; Ross et
al., 2003).
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CHAPTER VI: MYC expression is essential for TEL-AML1
leukaemia
6.1 Introduction
Classically, STAT3 has been considered to function as a transcription
factor and only recently has it been shown to have a function independent of
regulating gene expression. In response to activation, STAT3 is
phosphorylated on Tyr-705 and forms homodimers through phosphotyrosine-
SH2 domain interactions. In addition, STAT3 is able to dimerize with other
STAT proteins. It has been shown, for instance, that it can bind and synergise
with STAT4 in Human T-lymphotropic virus Type I (HTLV)-I-transformed T-cell
lines. Under particular conditions, formation of STAT3/STAT5 and
STAT3/STAT1 heterodimers has been also reported (Higashi et al., 2005;
Novak et al., 1996; Stancato et al., 1996). Following dimer formation, these
complexes translocate into the nucleus, bind to DNA elements within the
promoter regions of specific target genes and regulate transcription. However,
studies have revealed that STAT3 can pass across the nuclear membrane
even in an unphosphorylated state and that it dynamically shuttles between
cytoplasmic and nuclear compartments, acting in the nucleus as a
transcriptional activator/repressor and a chromatin/genomic organizer
(Timofeeva et al., 2012; Yang et al., 2005). By analogy, however, masking of
the dimerization site by binding of importin-α5 to unphosphorylated STAT1, 
suggests that nuclear importation through this mechanism would only function
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for unphosphorylated STAT3 monomers (Reich and Liu, 2006). Moreover,
STAT3 has been found to contain a constitutive nuclear localization signal
(NLS) within its coiled-coiled domain which can be recognized by the importin-
α3 and -α6 nuclear transport factors regardless of its phosphorylation status 
(Liu et al., 2005). Once in the nucleus, STAT3 can be phosphorylated on serine
residue 727 (Ser-727) by several kinases, including ERK1, ERK2, p38, JNK,
and protein kinase C (PKC) (Decker and Kovarik, 2000). This phosphorylation
is thought to increase the DNA binding affinity of STAT3 (Ng and Cantrell,
1997; Zhang et al., 1995). The requirement for a phosphorylated Ser-727 in
STAT3 may vary depending on the the target promoter subject to
transcriptional regulation and/or cellular types, and phosphorylation of this
residue can occur independently to that of the Tyr-705 residue. Molecules of
activated STAT3 then interact with transcriptional co-activators, such as
histone acetyltransferases, to induce transcription. Alternatively, they can
associate with protein complexes containing histone deacetylases to induce
transcriptional repression.
The gene set regulated by STAT3 is thought to vary between cell types
and differentiation stage of the cell in question. A recent study by Diego
Miranda-Saavedra’s group clearly illustrated this concept. They studied STAT3
genome-wide binding patterns in four different cell types: embryonic stem cells,
CD4+ T cells, macrophages and AtT-20 corticotroph cells. They found that only
a very small number of STAT3-binding sites were common to all four of the cell
types analyzed. Binding to these sites enabled regulation of a core set of genes
166
that are pre-bound by MYC, E2F1 and other transcriptional factors. In addition,
they showed that most of the genes bound by STAT3 are cell type-specific and
therefore responsible for the distinct biological outcomes of STAT3 activation in
the various different cell types (Hutchins et al., 2013). These differences may
be explained by the binding of STAT3 to variant DNA motifs or by the different
transcriptional regulatory modules able to assemble around STAT3 in the
different cell types to drive distinct transcriptional programs, as has been
demonstrated for other transcription factors, such as SMAD2/SMAD3 (Mullen
et al., 2011). This would mean that the interactions between STAT3 and
associated transcription factors, as a result of either direct protein-protein
interactions or resulting from binding of neighbouring sequences, may be
responsible for the distinct patterns of gene induction in different cell types. In
order to examine the consequences of STAT3 activation in human TEL-AML1+
cells, we decided to examine changes in the expression of potential candidate
target genes upon STAT3 inhibition mediated by S3I-201 treatment or shRNA
silencing.
6.1.1 SURVIVIN and MYC are transcriptionally regulated by STAT3
Although STAT3 controls distinct subsets of genes in different cancer
cells, a few of the target genes are common to most. Among these there are
genes encoding anti‑apoptotic proteins, such as SURVIVIN and members of
the Bcl-2 family (e.g., Bcl‑XL, Bcl-2), and proteins involved in proliferation and
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cell cycle progression, such as cyclin D1 and c‑MYC (Bromberg and Darnell,
2000; Dauer et al., 2005). In order to test the downstream effect of STAT3
inhibition in TEL-AML1 leukaemia we decided to examine the expression of
SURVIVIN and MYC, two well-characterized STAT3 target genes that have
been described to play important role in both normal haematopoiesis and in
cancer.
SURVIVIN, also known as BIRC5, is a member of the inhibitor of
apoptosis (IAP) protein family. The main function of this protein is to inhibit cell
death induced by caspase activation, however the mechanisms by which
SURVIVIN protects from apoptosis still remain unclear (Li et al., 2008). In
addition, it also functions in regulating cell division due to its ability to bind
microtubules of the mitotic spindle through its carboxyl-terminal alpha helices
(Li et al., 1999). SURVIVIN expression is limited to embryonic tissues, to cells
undergoing differentiation and to most cancer cells, whereas in terminally
differentiated cells its expression is almost completely absent (Ambrosini et al.,
1997). During the cell cycle, SURVIVIN is expressed in the G2/M phase and
promotes the proper segregation of chromosomes (Lens et al., 2003). Due to
its function in cell division and apoptosis, SURVIVIN is overexpressed in many
cancers and its expression has been correlated with drug-resistance in
particular tumours (Zaffaroni and Daidone, 2002). In t(12;21) leukaemia, a
direct link has been established between the TEL-AML1 fusion protein and
SURVIVIN. Thus, TEL-AML1 silencing was shown to result in reduced
SURVIVIN expression (Diakos et al., 2007; Diakos et al., 2010), its regulation
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being mediated via two different miRNAs (miRNA-494 and miRNA-320a)
(Diakos et al., 2007; Diakos et al., 2010). SURVIVIN has been shown also to
be a direct transcriptional target of STAT3 in different models (Aoki et al., 2003;
Gritsko et al., 2006; Sen et al., 2012).
c-MYC was discovered in 1982 as the gene encoding a transcription
factor homologue of the viral oncogene (v-MYC), from the avian
myelocytomatosis retrovirus (Vennstrom et al., 1982). c-MYC belongs to the
MYC family of transcription factor genes, which also include the n-MYC and l-
MYC genes. As in STAT3 signalling, many different mitogenic factors and
growth promoting stimuli converge upon c-MYC, stimulating and regulating
both its expression and transcription factor activity. For this reason, it plays a
fundamental role in replication, growth, apoptosis and differentiation. Targeted
homozygous deletion of the murine c-Myc gene resulted in embryonic lethality,
suggesting a critical function during development (Davis et al., 1993).
Interestingly, foetal death occurred around day 10.5, coincident with the onset
of foetal liver haematopoiesis, suggesting an important function of c-MYC in
regulating correct haematopoietic development. Significantly, one of the main
characteristics in these mice was the presence of circulatory defects. A study
of mouse embryos conditionally deficient in c-Myc expression, specifically in
the haematopoietic lineage, showed the same phenotype as those lacking c-
Myc in the entire embryo, confirming its role in this developmental process.
Thus, deletion of c-Myc solely in haematopoietic cells, resulted in embryonic
lethality due to a failure in normal development of haematopoietic cells, that
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resulted in a defect in angiogenesis (He et al., 2008). It has been shown,
moreover, that not all MYC family members are expressed in haematopoietic
stem/progenitor stem cells and those members that are expressed are always
co-expressed with c-MYC (Laurenti et al., 2008). In adult haematopoiesis, c-
MYC plays an important role for stem cell maintenance and differentiation. It
controls the interaction between HSCs and the bone marrow niche by
regulating expression of many adhesion-related molecules, including N-
cadherin and integrin-β1, -α2, and -α5, in HSCs (Wilson et al., 2004). c-MYC
also has a role during the differentiation of both lymphoid and myeloid cells. It
is expressed, together with n-MYC, during the maturation and expansion of the
earliest B precursor cells, and constitutive expression of c-MYC has been
shown to result in elevated numbers of B progenitors. On the other hand,
compound deletion of c-Myc and N-Myc family members caused a block in B
cell development at the pro-B to pre-B transition (Habib et al., 2007). This
suggests a possible link between MYC function and STAT3 signalling in
regulating B cell maintenance and expansion, since conditional deletion of
Stat3 in progenitor cells in the bone marrow results in a block at the same
stage of B cell development (Delgado and Leon, 2010). A link between c-MYC
and STAT3 has been well established. Firstly, different studies have shown
that c-MYC is a direct transcriptional target of STAT3 (Bowman et al., 2001;
Cartwright et al., 2005; Kiuchi et al., 1999; Ling and Arlinghaus, 2005).
Interestingly, experiments using a murine pro-B cell line (Baf-3) showed that
activation of STAT3 leads to increased c-MYC expression (Kiuchi et al., 1999).
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Secondly, it can function as cooperating factor to regulate STAT3
transcriptional activity by binding at the same time DNA sequences in the same
promoter synergizing or modulating the gene expression (Barre et al., 2005;
Hutchins et al., 2013).
Constitutive or deregulated expression of c-MYC is a characteristic of
most cancers. For example, genetic alterations in c-MYC have been reported
to contribute to one-seventh of U.S. cancer deaths (Dang, 1999). The first
human tumour in which c-MYC deregulation was identified was Burkitt’s
lymphoma (Dalla-Favera et al., 1982; Taub et al., 1982). c-MYC has since
been shown to be altered or its expression up-regulated in many others
haematological diseases, including both adult and childhood ALL (Delgado and
Leon, 2010; Faderl et al., 2010). Taken together, these reports suggest that c-
MYC may be critically important in malignant as well as normal
haematopoiesis.
6.2 Results
6.2.1 c-MYC is transcriptionally regulated by STAT3 in TEL-AML1
leukaemia
In addition to its reported function in malignant haematopoiesis, c-MYC
is also a well characterised transcriptional target of STAT3 signalling. For these
reasons, we decided to examine whether c-MYC expression was regulated by
STAT3 signalling in t(12;21) ALL. We treated TEL-AML1+ cell lines and the
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non-TEL-AML1+ cell line 697, with S3I-201 for 6 hours in order to isolate
mRNA, and 24 hours for protein analysis. This analysis demonstrated a
marked reduction in c-MYC mRNA (Figure 6-1A) and complete loss of c-MYC
protein in Reh and At-2 cells following exposure to 50µM S3I-201 (Figure 6-
1B). In contrast, there was only a modest reduction in c-MYC mRNA (Figure 6-
1A) and protein in 697 cells (Figure 6-1C). According to our model, activation of
STAT3 in TEL-AML1 leukaemia is mainly mediated by RAC1. In order to
further validate this hypothesis we decided to test the expression of c-MYC
upon treatment with NSC 23766. The results showed a reduction of both
mRNA and protein similar to that obtained by inhibiting STAT3 (Figure 6-2A
and 2B), suggesting a strong dependence of c-MYC expression upon RAC1
activity. Importantly, the reduction in c-MYC expression in 697 cells was
detectable only with S3I-201 treatment, but not with NSC 23766 (Figure 6-1A,
2A), indicating that this signalling pathway may be specific to TEL-AML1
leukaemia.
Since S3I-201 treatment of TEL-AML1+ cells results in apoptosis, it is
possible that the reduction in MYC protein expression observed was an indirect
result of the loss in cell viability. In order to examine this possibility, we
measured MYC protein expression in Reh cells after 4 hours exposure to S3I-
201, at which point there was no detectable induction of apoptosis (Figure 6-
3A). Despite the lack of apoptotic response at this time-point, S3I-201
treatment nevertheless caused a significant reduction in MYC protein
expression (Figure 6-3B). This suggests that the reduction in MYC expression
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is due to a direct effect of STAT3 inhibition, rather than non-specific cell death.
Down-regulation of c-MYC protein was also confirmed after shRNA-mediated
STAT3 silencing (Figure 6-4A). Furthermore, silencing of TEL-AML1 also
resulted in reduced c-MYC expression (Figure 6-4B), confirming the function of
this fusion protein in maintaining elevated STAT3 activity in leukaemic cells.
Although these data indicate that c-MYC expression requires STAT3
signalling in TEL-AML1+ cells, they do not address the importance of c-MYC
expression for growth and survival of these cells. To examine the importance of
c-MYC expression in TEL-AML1 leukaemia, we decided to analyse the effect of
silencing c-MYC directly in TEL-AML1+ cell lines cells (Figure 6-5A). Knock-
down of c-MYC in Reh cells resulted in similar induction of apoptosis and
inhibition of cell cycle progression as that observed after STAT3 knock-down
(Figure 6-5B, C). Furthermore, it also resulted in a complete a loss of self-
renewal activity in colony forming assays (Figure 6-6). This suggested that c-
MYC silencing may impair the ability of Reh cells to engraft leukaemia in vivo.
In order to examine this possibility, Reh cells were transduced with control
scramble or c-MYC shRNA expressing vectors and 48 hours later an
equivalent number of viable cells were transplanted into sub-lethally irradiated
recipient NSG mice. As predicted, c-MYC silencing resulted in a prolonged
latency of leukaemia development in vivo (Figure 6-7). Despite these data, it
was nevertheless possible that the requirement for STAT3 induced c-MYC
expression in the TEL-AML1+ cell lines was associated with their proliferative
status. For this reason we also examined c-MYC expression in two primary
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patient t(12;21) ALL samples following exposure to S3I-201. Although these
leukaemia cells samples did not proliferate when placed in vitro, S3I-201
treatment abolished c-MYC protein expression, consistent with the data
obtained in Reh cells (Figure 6-8).
6.2.2 SURVIVIN is transcriptionally regulated by STAT3 in TEL-
AML1 leukaemia
In order to examine the effect of STAT3 inhibition on SURVIVIN
expression, we measured the level of SURVIVIN mRNA expression in TEL-
AML1+ cell lines after 6 hours exposure to 50µM S3I-201, and protein levels 24
hours after exposure. In both cases, inhibition of STAT3 activity resulted in
reduced levels of SURVIVIN expression in the cells (Figure 6-9A, B). Moreover,
in order to show the validity of the RAC1-STAT3 pathway in downstream
regulation of SURVIVIN expression, we analysed gene expression after RAC1
inhibitor treatment. Treatment of cells with NSC 23766 resulted in similar
reductions of SURVIVIN expression, confirming upstream regulation of STAT3
activity via RAC1 (Figure 6-9C).
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6.3 Discussion
Although the target genes transcriptionally regulated by STAT3 may
vary between different cell types and cancers, our data demonstrate that in
TEL-AML1+ ALL there is an absolute requirement for STAT3 activity in the
maintenance of expression of two established target genes: BIRC5 and c-MYC.
We focussed our experiments on c-MYC, given the widely reported oncogenic
activity this gene. Our results demonstrate that loss of c-MYC expression in
TEL-AML1+ cells causes cell death and, importantly, a significant delay of
leukaemia development in vivo.
Aberrant expression of c-MYC has been demonstrated previously in
paediatric acute lymphoblastic leukaemia, including t(12;21) ALL, by Malempati
et al (Malempati et al., 2006). In this study, analysis of protein stability revealed
that the half-life of c-MYC protein was prolonged in the majority of the cases.
Contrary to what has been observed in other diseases, such as in Burkitt’s
lymphoma (Bahram et al., 2000), this increase in stability was not due to the
presence of somatic mutations in the c-MYC gene, but was caused by
deregulation of pathways controlling the phosphorylation of threonine 58 and
serine 62, the two amino acid residues that determine c-MYC stability
(Malempati et al., 2006). Our data that suggest that increased c-MYC
expression may also result from transcriptional induction of c-MYC gene
expression by STAT3 activation. Taken together, these data indicate a
fundamental role for c-MYC in TEL-AML1 leukaemia.
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A new concept for how c-MYC functions in transcriptional regulation
have recently emerged. Two papers showed that c-MYC acts as a non-linear
amplifier of gene expression rather than functioning as a traditional
transcription factor (Lin et al., 2012; Nie et al., 2012). Using genome-wide
analysis of c-MYC gene occupancy and the resulting changes in gene
expression, the authors of both studies concluded that c-MYC associates with
promoters of genes that are already actively transcribed and that this
association enhances transcriptional output further (Lin et al., 2012; Nie et al.,
2012). If this concept is true, the requirement for elevated c-MYC expression in
TEL-AML1 leukaemia could be explained by the possibility that it is essential
for the transcriptional activity of TEL-AML1 itself, thereby enhancing the
expression of genes regulated by the fusion protein.
Requirement of c-MYC up-regulation or stabilization could be also
necessary for the increased metabolic activity of the leukaemic cells. One of
the main characteristics of all cancer cells is the increased rate of proliferation
in comparison to normal cells. In order to increase the rate of cell division the
cells need to alter their metabolic activity to provide the necessary energy. This
metabolic shift has been well studied in solid tumour cells but there is evidence
that it also occurs in childhood pre-B acute lymphoblastic leukaemia. Thus,
Boag and colleagues demonstrated an altered expression of genes involved in
glycolysis and tricarboxylic acid (TCA) cycle in cells from ALL patients
compared to normal CD34+ cells (Boag et al., 2006). For example, there was a
significant up-regulation in expression of genes coding for glucose transport
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proteins (GLUT). These findings suggest that ALL cells may have a similar
metabolic profile to solid tumour cells. c-MYC plays an import role in this
process and has been shown to directly target many genes involved in
glycolysis, including GLUT1 (Dang et al., 2009). In addition to its role in
regulation of genes involved in glycolysis, c-MYC appears to increase
mitochondrial function, necessary for cell division. It has been shown, for
example, that c-MYC increases mitochondrial synthesis of acetyl-CoA which, in
turn, contributes to signiﬁcant increases in histone acetylation and fatty acid 
biosynthesis that allow the cells to divide faster (Morrish et al., 2010).
In conclusion c-MYC expression is essential for the survival of TEL-
AML1 leukaemia. However, further experiments are needed to clarify its role in
the regulation of gene expression changes induced by the fusion protein and
also to understand how it functions to modify metabolic activity in the
transformed cells.
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CHAPTER VII
7.1 Conclusions
The TEL-AML1 fusion gene has been considered to be a weak
oncogene and insufficient on its own for leukaemic transformation. Different
studies, including some carried out by our group, have previously
demonstrated that its presence is able to perturb haematopoietic pathways
promoting in vitro B cell differentiation and predispose haematopoietic stem
cells to generate overt leukaemia after acquisition of secondary genetic
alterations (Morrow et al., 2004; Schindler et al., 2009). The identification of the
specific pathways altered by the fusion gene itself has only recently become a
focus of study. The data collected so far, however, have only partially
demonstrated an active role for TEL-AML1 in deregulating specific pathways.
In 2009, for example, Ford and colleagues demonstrated that TEL-AML1 is
able to reduce the sensitivity of haematopoietic cells to TGFβ (Ford et al., 
2009). Analysis of gene expression after TEL-AML1 silencing in human TEL-
AML1+ leukaemic cell lines revealed an active function of the fusion protein in
activating the PI3K/AKT/mTOR pathway. However, this study did not describe
how this is achieved (Fuka et al., 2012).
In this study, we demonstrate a novel signalling pathway important for
the maintenance of TEL-AML1 leukaemia and, for the first time, an active role
of TEL-AML1 in directly regulating an oncogenic pathway (Fgure 7.1). In our
model, TEL-AML1 activates RAC1 which, in turn, induces STAT3 activation.
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STAT3 activation is necessary for the survival, proliferation and self-renewal of
TEL-AML1 positive leukaemia, through transcriptional induction of MYC
expression. We demonstrate, in fact, that human leukaemic cell lines carrying
this translocation are highly sensitive to treatment with S3I-201, a specific
STAT3 inhibitor, and that primary human leukaemic samples are also
responsive to this drug.
Although clinically, TEL-AML1 positive patients have excellent
outcomes, relapses are reported to occur in 10-20% of children and at the
moment there is insufficient data on the long-term effects of chemotherapy.
STAT3 inhibition may hence provide an alternative therapeutic approach
capable of overcoming both of these problems. STAT3 targeted therapy in
TEL-AML1 leukaemia may in fact have several beneficial effects. First, short-
term STAT3 treatment has been shown to not have severe side effects
(Kortylewski et al., 2005; Lee et al., 2011). Second, treatment with STAT3
specific inhibitors has been associated with an increment of innate and
adaptive immune responses to cancers (Kortylewski et al., 2005; Lee et al.,
2011). This may be as important as the direct inhibitory effects of the drug on
the leukaemic cells since there is increasing evidences for how the
microenvironment could influence leukaemic transformation and maintenance
of cancer clones (Purizaca et al., 2012). Third, although MYC is one of the
most de-regulated proteins in human cancers, targeting this protein has been
always a challenge. Its ubiquitous expression in all proliferating cells,
suggesting that its inhibition may be associated with unacceptable toxicities,
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and the difficulty in designing efficacious inhibitors have been the main reasons
for the failure of MYC targeting (Prochownik and Vogt, 2010). STAT3 inhibition
could be a way to bypass these difficulties in targeting MYC in TEL-AML1
leukaemia.
Our data propose that activation of RAC1 is mainly mediated by the
specific GEF ARHGEF4. Inhibition of the ARHGEF4 gene by shRNA mediated
silencing results in complete cell death and loss of engraftment in NSG mice,
suggesting that ARHGEF4 targeting could be of therapeutic interest. However,
with the current technology available, the shape, structural dynamics and
chemistry of GEF–GTPase interaction surfaces make it very difficult to develop
small molecule inhibitors (Vigil et al., 2010). Our results suggest that regulation
of ARGHEF4 in TEL-AML1 leukaemia is mediated by transcriptional activity of
the fusion gene. However, transcriptional regulation leading to elevated
ARHGEF4 expression alone may not be sufficient to fully activate the RAC1
protein. Moreover, in addition to being a specific activator of RAC1, ARHGEF4
may have an independent function in regulating the survival and proliferation of
leukaemic cells. For this reason developing new tools to study the function of
TEL-AML1 in regulating ARHGEF4 and the latter’s role in this subtype of ALL
will be promising in order to develop new therapeutic strategies to improve the
treatment of TEL-AML1 leukaemia.
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